Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - China Health Industries Holdings, Inc.exhibit31-1.htm
EX-32.1 - EXHIBIT 32.1 - China Health Industries Holdings, Inc.exhibit32-1.htm
EX-31.2 - EXHIBIT 31.2 - China Health Industries Holdings, Inc.exhibit31-2.htm
EX-10.14 - EXHIBIT 10.14 - China Health Industries Holdings, Inc.exhibit10-14.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.20549

FORM 10-K

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2016

or

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission file number: 000-51060

CHINA HEALTH INDUSTRIES HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware 86-0827216
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)  

168 Binbei Street, Songbei District, Harbin City  
Heilongjiang Province  
People’s Republic of China 150028
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 86-451-88100688

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.0001 par value
Title of Class

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
[   ] Yes     [X] No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
[   ] Yes     [X] No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[X] Yes     [   ] No


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
[X] Yes     [   ] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [   ] Accelerated filer [   ]
   
Non-accelerated filer [   ] (Do not check if a smaller reporting company) Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
[   ] Yes     [X] No

The aggregate market value of the voting and non-voting common stock of the issuer held by non-affiliates as of December 31, 2015 was approximately $6,754,882.35 (45,032,549 shares of common stock held by non-affiliates) based upon the closing price of the common stock on such date.

As of September 14, 2016, there were 65,839,737 shares of common stock, par value $0.0001 issued and outstanding.

2


Table of Contents

Part I    
     
Item 1 Business 4
     
Item 1A Risk Factors 19
     
Item 1B Unresolved Staff Comments 19
     
Item 2 Properties 19
     
Item 3 Legal Proceedings 19
     
Item 4 Mine Safety Disclosures 19
     
Part II    
     

Item 5

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

20
     
Item 6 Selected Financial Data 21
     
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 22
     
Item 7A Quantitative and Qualitative Disclosures About Market Risk 27
     
Item 8 Financial Statements and Supplementary Data 27
     
Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 29
     
Item 9A Controls and Procedures 29
     
Item 9B Other Information 30
     
Part III    
     
Item 10 Directors, Executive Officers and Corporate Governance 30
     
Item 11 Executive Compensation 34
     
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 36
     
Item 13 Certain Relationships and Related Transactions, and Director Independence 36
     
Item 14 Principal Accounting Fees and Services 36
     
Part IV    
     
Item 15 Exhibits, Financial Statement Schedules 38

3


PART I

Item 1. Business.

Our History and Corporate Structure

China Health Industries Holdings, Inc. (“China Health US”) was incorporated in the State of Arizona on July 11, 1996 and was the successor of the business known as Arizona Mist, Inc. which began in 1989. On May 9, 2005, it entered into a Stock Purchase Agreement and Share Exchange (effecting a reverse merger) with Edmonds 6, Inc. (“Edmonds 6”), a Delaware corporation, and changed its name to Universal Fog, Inc. Pursuant to this agreement, Universal Fog, Inc. (which has been in continuous operation since 1996) became a wholly-owned subsidiary of Edmonds 6.

China Health Industries Holdings Limited (“China Health HK”) was incorporated on July 20, 2007 in Hong Kong under the Companies Ordinance as a limited liability company. China Health HK was formed for the purpose of seeking and consummating a merger or acquisition with a business entity organized as a private corporation, partnership, or sole proprietorship as defined by FASB ACS Topic 915 (“Development Stage Entities”).

Harbin Humankind Biology Technology Co., Limited (“Humankind”) was incorporated in Harbin City, Heilongjiang Province, the People’s Republic of China (the “PRC”) on December 14, 2003, as a limited liability company under the Company Law of the PRC. Humankind is engaged in the manufacturing and sale of health products.

On August 20, 2007, the sole shareholder of China Health HK entered into a share purchase agreement (the “Share Purchase Agreement”) with the owners of Humankind. Pursuant to the Share Purchase Agreement, China Health HK purchased 100% of the ownership in Humankind for a cash consideration of $60,408 (the “Share Purchase”). Subsequent to the completion of the Share Purchase, Humankind became a wholly-owned subsidiary of China Health HK. The Share Purchase was accounted for as a “reverse merger” since the owner of Humankind owned a majority of the outstanding shares of China Health HK’s common stock immediately following the execution of the Share Purchase Agreement, it was deemed to be the acquirer in the reverse merger. Consequently, the assets and liabilities and the historical operations that have been reflected in the financial statements for periods prior to the Share Purchase are those of Humankind and have been recorded at the historical cost basis. After completion of the Share Purchase, China Health HK’s consolidated financial statements include the assets and liabilities of both China Health HK and Humankind, the historical operations of Humankind, and the operations of China Health HK and its subsidiaries from the closing date of the Share Purchase.

On October 14, 2008, Humankind set up a 99% owned subsidiary, Harbin Huimeijia Medicine Company (“Huimeijia”), with its primary business being manufacturing and distributing medicine. Mr. Xin Sun, the Company’s majority owner, owns 1% of Huimeijia. Huimeijia is consolidated in the consolidated financial statements of China Health HK.

On December 31, 2008, China Health HK entered into a reverse merger with Universal Fog, Inc., a U.S. publicly traded shell company (the “Transaction”). China Health HK is the acquirer in the Transaction, and the Transaction has been treated as a recapitalization of China Health US. After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US. On April 7, 2009, Mr. Sun transferred 28,200,000 shares of common stock to 296 individuals, leaving him with 33,003,088 shares of common stock of China Health US, or approximately 53.03% of the total outstanding shares of common stock. Universal Fog, Inc. changed its name to China Health Industries Holdings, Inc. on February 19, 2009.

On November 22, 2013, Humankind completed the acquisition of Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”) for a total purchase price of $16,339,869 (RMB100,000,000). HLJ Huimeijia was founded on October 30, 2003, and is engaged in the manufacturing and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. HLJ Huimeijia’s predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which has established its brand name in the market through its supply of high quality medical products. HLJ Huimeijia is categorized as a “high and new technology” enterprise by the Science Technology Department in Heilongjiang Province. HLJ Huimeijia has 21 products which have been approved by, and have received approval numbers issued by, the China Food and Drug Administration (“CFDA”). In addition, HLJ Huimeijia is the holder of one patent for utility models, five patents for external design and three trademarks in China, including the Chinese brand name of “Xue Du” which has an established reputation among customers in northeastern China.

China Health US, China Health HK, Humankind, Huimeijia and HLJ Huimeijia are collectively referred herein to as the “Company.”

4


Our corporate structure as of June 30, 2016 was as below:


Business Overview

Humankind was incorporated in the PRC on December 14, 2003, and completed its Good Manufacturing Practice (“GMP”) certificate on April 24, 2007, which will last until February 14, 2019 and is expected to extend after that. It is in the business of the manufacture and sale of health products.

Huimeijia was incorporated in the PRC on October 14, 2008. Huimeijia received its GMP certificate on July 23, 2009, which expired as of July 22, 2014. On December 24, 2014, Humankind entered into a stock transfer agreement (the “Agreement”) with Xiuzheng Pharmaceutical Group Co., Ltd. a company incorporated under the laws of the People’s Republic of China and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), Mr. Xin Sun, the CEO of the Company, and Huimeijia, pursuant to which, Humankind and Mr. Xin Sun (the “Equity Holders”), shall sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of the 100% equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) to the Equity Holders.

On February 9, 2015, the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy. The Equity Holders will retain the equity interests in Huimeijia, but will have the equity interests pledged to Xiuzheng Pharmacy until the Assets are transferred, at which time all the cash consideration shall be paid by the Buyer. The total cash consideration remains to be the same as under the Agreement, i.e., RMB 8,000,000 (approximately $1,306,186) to the Assets Transferors.

5


In the event that the Assets are failed to be transferred to the Buyer due to the fault of the Assets Transferors, the paid consideration shall be returned to the Buyer with interests accrued. If the failure of the transfer of the Assets is a result of the government policy changes or force majeure, the paid cash consideration shall be returned to the Buyer but without any interests. As of June 30, 2016, the transfer of the Assets had not been completed because the assets transfer crossed different provinces which resulted in a complicated interaction among the local administrations of Heilongjiang Province, where Huimeijia is located and Jilin Province, where the transferee is located. The Company is striving to accelerate the process of the transfer.

HLJ Huimeijia was founded on October 30, 2003, its latest GMP certificate was effective from November 12, 2009 to December 31, 2015. HLJ Huimeijia has applied a new certificate of GMP, which is expected to be obtained in April 2017. HLJ Huimeijia engages in the manufacture and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. Its predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which had established brand name in the market through its supply of high-quality drug products. HLJ Huimeijia is a “high and new technology” enterprise that provides the most comprehensive types of topical medical products in Heilongjiang Province, a northeastern province of China.

Our business is conducted through our PRC subsidiaries, Humankind and HLJ Huimeijia. Our products are primarily sold through sales agents. We plan to develop chain-stores to sell our products and to eventually sell our products online.

Products

We have, through Humankind, the license to manufacture and sell 14 health supplement products, each of which have been assigned a Guo Shi Jian Zi number, or China health food approval number (as provided below), an approval number issued by the China Food and Drug Administration (“CFDA”). A product with such a number shall include a description of the nourishment value and health function of the products on product specifications. Consumers can check the official website of CFDA to verify a health supplement product through such a number.

We have, through HLJ Huimeijia, the license to manufacture and sell 21 products. In addition, HLJ Huimeijia holds one patent for utility models, five patents for external design, and three trademarks in China, including the Chinese characters of “Xue Du,” which has a good reputation amongst customers in northeastern China.

We are licensed to sell our products, including our medical drugs, only in the PRC.

(i)

Health Supplement

Our “QunLe” brand Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine (made from grape seeds) and vitamin E, is for freckle removal and skin moisture supplements. The certification number issued by CFDA on September 3, 2013, is 2013B1097, with an expiration date on September 2, 2018.

On May 12, 2010, we received a patent for this product (number 200610010394.4) under the name “Run Chao” (which has since been changed to “QunLe”) with the National Bureau of Intellectual Property.

Pursuant to a technology transfer agreement dated October 12, 2007 (the “2007 Technology Transfer Agreement”), we purchased a health product known as “Kindlink” brand propolis and black ant capsule made from propolis, black ant, acanthopanax and astragalus root from Beijing Jindelikang Bio-Technology Co., Ltd (“Jindelikang”). The change of the ownership has been approved by the CFDA. This product is to boost one’s immunity. The certification number issued by the CFDA on August 20, 2004, for the license to manufacture the product is GuoShiJianZi G20040906. We have no continuing obligations under the 2007 Technology Transfer Agreement.

6


Pursuant to a technology transfer agreement dated January 18, 2013 (the “2013 Technology Transfer Agreement”), we purchased 12 health products from Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd, a non-affiliated party. These twelve products are the following:

- Dr. Xiao Brand Honeysuckle Pearl Capsule (Guo Shi Jian Zi G20100656), which is effective in acne removal, - Dr. Xiao Brand Multivitamin Tablet (Guo Shi Jian Zi G20080176), which is a multivitamin and mineral supplement, - Dr. Xiao Brand Zhengdian Capsule (Guo Shi Jian Zi 20070261), which is effective in relieving eyestrain, - Dr. Xiao Brand Shengui Capsule (Guo Shi Jian Zi G20080297), which is effective in increasing bone density,

- Dr. Xiao Brand Multivitamin Tablet (Woman) (Guo Shi Jian Zi G20070338), which is an iron and multivitamin supplement,

- Dr. Xiao Brand Shikong Soft Capsule (Guo Shi Jian Zi 20080096), which is effective in improving memory,

- Dr. Xiao Brand Huangjingdanggui Tablet (Guo Shi Jian Zi G20080201), which is effective in improving nutritional anemia and chloasma,

- Dr. Xiao Brand Xingxing Soft Capsule (Guo Shi Jian Zi G20080080), which is effective in improving memory,

- Dr. Xiao Brand Vitamin A Fish Oil Soft Capsule (Guo Shi Jian Zi G20080406), which is effective in relieving eyestrain,

- Dr. Xiao Brand Colon Cleanser Granules (Guo Shi Jian Zi G20060061), which is effective in relaxing bowels and promoting the discharge of lead,

- Dr. Xiao Brand Jianli Soft Capsule (Guo Shi Jian Zi G20050710), which is effective in increasing immunity and relieving physical fatigue, and

- LB Brand Xinpin Capsule (Guo Shi Jian Zi G20050770), which is effective in dispelling chloasma.

The major suppliers of raw materials for our products who exceeded 10% of our total purchases in the fiscal years 2016 and 2015 are the following:

    Purchases  
    (in U.S. % of
  Name of Supplier Dollars) Purchases
       
FY2016 Shukui Wang 3,851,964 78.08%
FY2015 Shukui Wang 4,874,929 73.87%

For the past two fiscal years, Mr. Shukui Wang has been our biggest supplier of raw materials.

The Company typically signs monthly purchase orders with its suppliers. All purchase orders with Mr. Wang and with our other suppliers are on similar terms. We shall remit payment to a supplier’s account no later than three business days after receiving raw materials. A supplier shall deliver raw materials no later than three business days after receiving a purchase order. The cost of delivery is borne by a supplier.

(iii)

Medical Drugs

Huimeijia purchased Harbin Dong Feng Medicine Company’s license to manufacture 19 medical drugs on September 16, 2008. As mentioned above, although Humankind, Mr. Xin Sun and Huimeijia has entered into the Agreement and the Supplementary Agreement with Xiuzheng Pharmacy to sell the 19 drug approval numbers to Xiuzheng Pharmacy, the transaction has not yet completed. Huimeijia remained the registered owner of the license, approved by the Heilongjiang Food and Medicine Supervising Bureau.

7


A description of the 19 medical drugs is as follows:

Serial No. Product Efficacy
     
1.

Stomach-Tonic Tablets

Invigorating stomach and relieving pain. Used in the treatment of pain from stomach distention, eructation with fetid odor and fecal disorders caused by gasterasthenia and dyspeptic retention.

 

 

2.

Pediatric Compound Sulfamethoxazole Tablets (0.125g)

Used in the treatment of:

 

1. Urinary tract infection caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Bacillus proteus and Proteus morganli.

 

2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Hemophilus influenza.

 

3. Acute episode of adult chronic bronchitis caused by Streptococcus pneumoniae or Hemophilus influenza.

 

4. Intestinal infection and Shigella infection caused by sensitive strains of Shigellaflexneri and Shigellasonnei.

 

5. Pneumonia caused by Pneumocystis carinii.

 

6. Prevention of pneumonia caused by Pneumocystis carinii. This product can be used for patients with a history of pneumonia caused by Pneumocystis carinii or adult HIV-infected patients whose CD4 lymphocyte count is dult HIV-infected patients whose CD4 lymphocyte countTurista caused by enterotoxic Escherichia coli.

 

3.

Pediatric Compound Sulfamethoxazole Tablets (0.25g)

Same as above.

 

4.

Pipemidic Acid Tablets

Used to treat urinary tract infection and bacterial infection of the intestines caused by sensitive gram negative bacilli.

 

5.

Metamizole Sodium Tablets

Used to relieve fever caused hyperpyrexia and also for headache, migrainous headache, courbature, arthralgia, menalgia etc. The product also has strong anti-rheumatism effects and can be used for acute rheumatic arthritis, but because the product may induce severe adverse reaction, it is seldom applied  in the treatment of rheumatic diseases.

8



6.

Paracetamol Tablets

Used for fever caused by common cold or epidemic influenza and also for relieving light and moderate pain such as headache, arthralgia, migraines, tooth ache, courbature, neuralgia and menalgia.

 

7.

Pediatric Paracetamol, Artificial Cow- bezoar and Chlorphenamine Maleate Tablets

Used to relieve fever, headache, aching pain in extremities, sneezing, rhinorrhea, nasal obstruction, pharyngodynia and other symptoms in children caused by common cold or epidemic influenza.

 

8.

Compound Theophylling Hydrochloride Tablets

Used to treat bronchial asthma.

 

9.

Powerful Loquat Syrup

Used for the treatment of coughing and reduction of sputum caused by bronchitis.

 

10.

Purple Orange Cough Syrup

Relieving cough and eliminating sputum. Used to relieve coughing and excessive phlegm as well as expectoration.

 

11.

Cough Syrup of Loquat Leaf

Used to clear lungs, relieve coughs and eliminate sputumand excessive phlegm.

 

12.

Children’s Cough Syrup

Eliminating phlegm and relieving cough. Used to relieve coughs caused by the common cold in children.

 

13.

Pentoxyverine Citrate and Ammonium Chloride Syrup

Used for cough and expectoration.

 

14.

Schisandra Syrup

Tonifying vital energy and invigorating the kidneys. Used in the treatment for neurastheria, dizziness and insomnia

 

15.

Ginseng Oral Liquid

Used to nourish renal “qi” and promote fluid production to quench thirst. Used to treat fatigue and acratia caused by deficiency of vital energy as well as poor appetite, cardiopalmus and shortness of breath, insomnia and forgetfulness.

 

16.

Compound Fluououracil Oral Solution

Used in the therapeutic treatment of digestive tract cancer (colon carcinoma and gastric carcinoma), mammary adenocarcinoma, primary hepatic carcinoma.

 

17.

Gossypol, Potassium Chloride and Vitamins B Capsules

Used in the treatment of uterine bleeding brought on by menopause.

 

18.

Compound Belladonna and Aluminum Hydroxide Powder

Used for relieving stomach pain, brash (heartburn) and acid reflux caused by gastric hypersecretion.

 

19.

Gentian and Sodium Bicarbonate Powder

Used for anorexia, gastric hypersecretion and dyspepsia.

9


In addition, HLJ Huimeijia has 21 products with approval numbers issued by the CFDA as following:

  English Name Efficacy
1

Enema Glycerini

Lubricating laxative. Used for constipation.

 

2

Umguentum Acidi Borici Camphoratum

Dermerethistica. Used for chilblain.

 

3

Ge Hong Beriberi Water

Dehumidification insecticide. Used for tinea pedis and tinea manuum caused by damp toxin brewing and binding, and other skin diseases caused by enzyme.

 

4

Pelvic Inflammation Suppository

Heat-clearing and detoxifying; activating blood to promote menstruation disperse swelling and relieve pain. Used for toxin and blood stasis stagnation in the uterus, distending pain in the lower abdomen, irregular menses, algomenorrhea and leukorrhagia, as well as pelvic inflammation and annexitis with the aforementioned symptoms.

 

5

Injury and Paralysis Tincture

Warm channel and expelling cold, promoting blood circulation to arrest pain. Used to relieve pain caused by traumatic injury and sprain.

 

6

Indometacin and Furazolidone Suppositories

Anti - inflammatory painkiller. Used to treat acute hemorrhoid, including internal hemorrhoids, external hemorrhoids, mixed hemorrhoids, anal fissure or archosyrinx and relieve pain; Used to ease pain after the operation of anal fissure, archosyrinx or hemorrhoids.

 

7

Injury and Rheumatism Relieving Paste

Dispelling rheumatism and relieving pain. Used for headache, rheumatalgia, neuralgia, sprain and muscular soreness.

 

8

Refining GouPi Cream

Relaxing tendon, invigorating the circulation of blood, dissipating cold and relieving pain. Used for arthralgia and myalgia, acute contusion, sprain, rheumatalgia, arthralgia, hypochondriac pain, muscular soreness, etc.

 

9

Muskiness Pain Relieving Paste

Expelling wind and removing dampness, relaxing the tendons and unblocking collateral. Used for rheumatic arthralgia, low back cold pain, traumatic injury, etc.

 

10

Muskiness Bone Strengthener Paste

Analgesia and anti-inflammatory. Used for rheumatalgia, arthralgia, backache, neuralgia, muscular soreness, sprain and contusion.

 

11

Matrine Suppositories

Antibacterial and antiphlogistic drugs. Used for trichomonas and candida vaginitis, chronic cervicitis, pelvic inflammation, etc.

 

12

Ethacriding Lactate Solution

Disinfectant and preservative drug. Used for disinfection of traumatic and disinfected wounds.

 

13

Triamcinolone Acetonide and Neomycin Paste

Used for neurodermatitis circumscripta and chronic eczema. Also used for small-scale psoriasis.

10



14

Double – Coptis Suppository

Course wind and resolving the exterior, heat-clearing and detoxifying. Used for influenza caused by affection of exogenous wind-heat, with symptoms of fever, cough and sore throat. Also used for upper respiratory tract infections and pneumonia, with symptoms of fever, cough and sore throat.

 

15

Methylrosanilinium Chloride Solution

Disinfectant and preservative drug.

 

16

Iodine Tincture

Disinfectant and preservative drug.

 

17

Mercurochrome Solution

Disinfectant and preservative drug.

 

18

Hydrogen Peroxide Solution

Disinfectant and preservative drug.

 

19

Halcinonide Cream

Grucocorticoid. External use drug only to be used on the skin. Used for dermatoneuritis and psoriasis.

 

20

Compound Fluocinonide Tincture

Grucocorticoid. Used for dermatoneuritis and psoriasis.

 

21

Policresulen Vaginal Suppository

Anti-microbial and hemostasis drug.

Distribution

We signed a non-exclusive cooperation agreement with the Commercial Bureau of Qing’an County, Heilongjiang on September 17, 2008. Under the agreement, various affiliated companies of the Commercial Bureau provides organic food and green food products to us for distribution and sale throughout the PRC.

We order products from the Commercial Bureau and such products are delivered within 20 days of placing the order. The prices for these products fluctuate within a 3% range from its wholesale price, but we are not restricted in any way in dictating the retail prices for such products. We typically have an average profit margin of approximately 20%.

Most of our products are sold to sales agents. In the fiscal year of 2015, our sales network covered 25 provinces and 4 Municipalities in China and our products were mainly sold in Beijing, Zhejiang, Jiangsu, Shanghai, Gansu, Anhui, Jilin and Shandong provinces or cities. In the fiscal year of 2016, due to the update of GMP certificate which prevents HLJ Huimeija from selling products during this period, our sales network covered 11 provinces and 4 Municipalities in China and our products were mainly sold in Beijing, Zhejiang, Jiangsu, Shanghai, Gansu, Anhui, Jilin and Liaoning provinces or cities.

E-business

We are in the process of building the infrastructure to conduct our business over the internet. A B2C e-business call and sales center has been established and will become an integral part of our distribution channel in the future. We have employed graduates from Tsinghua University, Harbin Industry University and Harbin Engineering University to develop the ERP, CRM and Office Automation software (“OA Software”) for our e-business. The OA Software has been used in our daily operation. The Company plans to sell its products via internet in the fiscal year of 2017.

Our Customers

We sell most of our products to sales agents, who are our customers. The sales agents sell the products to the end users.

11


Our customers who contributed more than 10% of our consolidated revenues during the past two fiscal years are as following.

         

Sales (in

 

 

 

   

   

U.S.

 

 

Percent of

 

Name  

Products Sold

   

Dollars)

 

 

Sales

 

FY2016  

             
   

             
Hao Liu  

Waterlilies Soft Capsule, Propolis and Black Ant Capsule

    917,000     11.73%  
   

         
Yufeng Shen  

Waterlilies Soft Capsule, Propolis and Black Ant Capsule

    893,113     11.43%  
   

         
Xiaomei Xu  

Waterlilies Soft Capsule, Propolis and Black Ant Capsule

    824,129     10.54%  
   

         
Dawei Shen  

Waterlilies Soft Capsule, Propolis and Black Ant Capsule

    812,173     10.39%  
   

         
FY2015  

 

             
   

         
Hao Liu  

Waterlilies Soft Capsule, Propolis and Black Ant Capsule

    1,109,209     10.85%  
   

         
Yufeng Shen  

Waterlilies Soft Capsule, Propolis and Black Ant Capsule

    1,100,924     10.77%  

Manufacture

We manufacture our health food products on a plot of land located in Jin Xing Industrial Park, Songbei District, Harbin. On June 7, 2004, the Company entered into a Land Use Purchase Contract with the local government, pursuant to which the Company agreed to purchase the right to use a piece of land, approximately 8 acres (32,000 square meters), located in Harbin City, Heilongjiang Province for commercial purposes for a fifty-year period from June 7, 2004 through June 6, 2054, for $637,261 (RMB5,248,000). The Company has fully paid to the government the consideration for the land use right on June 13, 2004. The Department of Housing and Urban Development of Harbin City approved this transaction. The Company is in the process of applying for the title certificate from the local government. The manufacturing facility on the land is 4,000 square meters and there are five production lines which are sufficient for our purposes. We package our products in bottles, plastic containers and aluminum foil bags there.

After we acquired HLJ Huimeijia on November 22, 2013, we also manufacture our medicines and drugs using HLJ Huimeijia’s land, approximately 43,350 square meters, located in Hai-lin Economic Development Zone, Mudanjiang City. The manufacturing facilities occupy approximately 5,710 square meters. We plan to build new manufacturing facilities on the land. The expected construction cost is approximately $7,520,000 (RMB 50,000,000).

Our Development Strategy

We will focus on combining our products with traditional Chinese medicine, the creation of new products, and developing our B2C e-business and chain-stores. We plan to implement health management projects in our future chain-stores throughout China and establish a database of our clients’ health data obtained from our B2C e-business and call center.

We plan to establish a one-stop shop for our customer’s health needs. From conducting a genetic profile of our customer to determine his/her susceptibility to certain types of diseases and then customizing health supplements and organic/green food to meet his/her needs, we plan to cater to our customer’s needs at all levels. With the distribution network we hope to establish through our chain stores and B2C e-businesses, we plan to eventually branch into the sale and distribution of beauty products and medical appliances.

12


The Future

Within the next ten years, our goals are to:

  1.

Increase product coverage in target markets; achieve 20%-30% coverage

Our target market is the health industry market. Presently, we believe that our product coverage is approximately 0.2% . We plan to open distribution stores in different provinces of China to expand our coverage. We also plan to sell our products through B2C websites to our customers.

  2.

Enter into the medicine, health product, health industry top 500 companies in the PRC

Currently, we are not ranked in the top 500 medicine, health product and health industry companies in the PRC. We believe that if our projected increase in revenue is achieved, we will achieve our goal of becoming one of the top 500 medicine, health product, health industry companies in China.

  3.

Form a diversified management group

Currently, our management group comprises people graduated from the most prestigious universities in the PRC, such as Peking University and Renmin University of China. We plan to further diversify management group by hiring talent both in the PRC and abroad.

  4.

Enter into the international market and create an internationally famous brand

Currently, our products are sold under the brand names “Qunle”, “Kindlink”, “Huimeijia” and “Dr. Xiao” in the PRC. Our goal is eventually to expand our sales abroad to countries such as the United States of America, Russia, and Eastern Europe and South-east Asian countries.

Our Business Plan

The plans designed to meet our manufacturing, marketing and profit targets include:

Manufacturing:

  (a)

improving the manufacturing techniques and staff training;

     
  (b)

guaranteeing high quality material supply;

     
  (c)

strengthening the working procedure controls;

     
  (d)

implementing GMP to ensure a compliance standard in the food and medical industries;

     
  (e)

ensuring that all employees have adequate training in health regulations.

Marketing:

Adopt an effective marketing mode to:

  (a)

utilize direct distribution of products to chain stores nationwide;

13



  (b)

build business alliances with well-known enterprises to create private label brands;

     
  (c)

expand the marketing of our products beyond the traditional methods.

Product Distribution:

  (a)

enlarge our sales and marketing force while developing new markets;

     
  (b)

strengthen the distribution channel by developing promotion strategies and participating in trade shows;

     
  (c)

develop 1-3 new products to market each year;

     
  (d)

develop new markets through innovation and research.

Our approach to manufacturing, marketing, cost control and products distribution, which is detailed above, is designed to minimize production costs and increase revenue at the same time. We feel that our procedures will enable us to reach our sales goals with an optimal manufacturing cost. The result should yield profits and a return to our investors.

Good Manufacturing Practice or “GMP” is a term that is recognized worldwide for the control and management of manufacturing and quality control testing of foods and pharmaceutical products. An important part of GMP is documentation of every aspect of the process, activities, and operations involved with drug and medical device manufacture. Additionally, GMP requires that all manufacturing and testing equipment has been qualified as suitable for use, and that all operational methodologies and procedures (such as manufacturing, cleaning, and analytical testing) utilized in the drug manufacturing process have been validated (according to predetermined specifications), to demonstrate that they can perform their purported function(s).

The Market for Healthcare and Beauty Products

The health product industry is one of the mainstream industries in the PRC, since it has a high level of recognition and importance. Recently there have been new policies for health products, which control quality, manufacturing, manufacturing environments and techniques. With the PRC’s large and aging population there will be a steady demand for healthcare products. It is predicted that the healthcare and beauty industry will flourish over the next 50 years.

The Healthcare Product Market in the PRC

With thousands years of history in health culture and traditional Chinese medicine, PRC currently utilizes advanced technique and production capacity to initiate a new round of health care trend, from drugs and medicines to traditional health food and nutritional supplements, and from medical devices to health management and advices. The trend demonstrates huge potential in PRC’s health products market.

Compared with the U.S. and Australia, the Chinese domestic industry of healthcare products is emerging. The scale of this industry in 2014 is $14 billion. The per capita consumption level is $56 in the U.S., $41.6 in Australia, and $11.4 in China. According to the forecast conducted by Bain and Company, the scale of the industry in China will increase by 8% each year in the following four years, and reach $19.6 billion in 2018.

According to a report issued by BCG, the global management consulting firm based in Boston, titled “From Insight to Action: Capturing a Share of China’s Consumer Health Market”, Chinese consumers are increasingly health conscious and China’s growing health and wellness market is expected to reach nearly $70 billion by 2020.

Competition in the Healthcare Products Industry

We believe our competitors are:

Harbin DaZhong Pharmaceutical Co., Ltd.(Located in Harbin, Heilongjiang Province);

14


Tsinghua Unisplendour Corporation Limited (Located in Weihai City, Shandong Province);

Yeecare Company (Located in Beijing);

Heilongjiang Tianlong Pharmaceuticals Co., Ltd (Located in Heilongjiang Province); and

HPGC Renmintongtai Pharmaceuticals Co., Ltd (Located in Heilongjiang Province).

Our Competitive Advantages and Strategy

We believe that we have the following competitive advantages over our competitors:

 

We have more categories of products and a diversified production line;

     
 

We have a strong and effective research and development team;

     
 

We are a self-owned enterprise, and have the support of the local government;

     
 

We have a geographical advantage being located in Heilongjiang Province, the center of the healthcare industry in the PRC.

Sales and Marketing

We plan to open more chain stores throughout the PRC. Customers who are members of our stores could enjoy discounted price of our products and services. After establishing enough stores, we plan to develop a 24-hour delivery system for our B2C e-business.

We did not incur expenses for advertising and promotion for the fiscal year of 2016. We have budgeted approximately $500,000 for advertising and promotion for the fiscal year of 2017.

Intellectual Property

We have received a patent (200610010394.4) for our “Qunle” brand Sailuozhi soft capsule from the National Bureau of Intellectual Property. We had initially applied for and used the trade name of “RunChao” soft capsules but the trade name was changed to “Qunle”, and the change has been approved by the National Bureau of Intellectual Property.

Pursuant to a Technology Transfer Agreement dated October 12, 2007 (“Kindlink Technology Transfer Agreement”), we purchased for a total of RMB350,000 the technology, manufacturing, and trademark rights to the health product known as “Kindlink” brand propolis and black ant capsule made from propolis, black ant, acanthopanax, astragalus root from Jindelikang. The change of the ownership has been approved by the CFDA. This product is consumed to boost one’s immunity. The certification number issued by the CFDA on August 20, 2004, to permit the manufacture of the product is GuoShiJianZi G20040906. We have no continuing obligations under the Kindlink Technology Transfer Agreement.

We have the following 15 trademarks(1):

 

Certificate

 

 

 

 

 

 

 

Trademark

 

No.

 

 

Category

 

 

Registrant

 

 

Valid Term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

“Qunle” with an arch image

 

3895929

 

 

No.5 : Dietetic foods adapted for medical purposes; Food preparations adapted for medical purposes; Albuminous milk; Dietetic beverages adapted for medical purposes; Milk sugar; Diabetic bread; Albuminous foodstuffs for medical purposes; Food for babies; Dietetic substances adapted for medical use; Nutritional additives for medical purposes  

 

 

Humankind

 

 

7/7/2006 to  7/6/2016(2)

15



“Qunle”

 

3896026

   

No.5 : Food preparations adapted for medical purposes; Albuminous milk; Dietetic beverages adapted for medical purposes; Milk sugar; Diabetic bread; Albuminous foodstuffs for medical purposes; Food for babies; Dietetic substances adapted for medical use; Nutritional additives for medical purposes

   

Humankind

   

7/7/2006 to 7/6/2016(2)

 

 

   

   

   

 

“Wangzu”

 

4857905

   

No.30: Molasses for food; Honey; pollen healthy grease; tortoise tuchahoe paste; breed columbine extract; helix alga; non-medicial nutrition liquid; non-medicial nutrition powder; non-medicial nutrition capsule; sugar candy bird’s nest

   

Humankind

   

5/14/2008 to 5/13/2018

 

 

 

   

   

   

 

“Kindlink”

 

3236981

   

No.5: Food preparations adapted for medical purposes; Dietetic substances adapted for medical use

   

Humankind

   

12/7/2013 to 12/06/2023

 

 

 

   

   

   

 

“Huimeijia”

 

5280303

   

No.5 : Medicine for human consumption; Medical nutrition capsule; Fibres (Edible plant) [non-nutritive]; Injection; Raw material drug; Troche; suppository; Food preparations adapted for medical purposes; Dietetic foods adapted for medical purposes; Dietetic substances adapted for medical use

 

Humankind

   

7/21/2009 to 7/20/2019

 

 

 

   

   

   

 

“Huide”

 

5280304

   

No.5 : Medicines for human consumption; Medical nutrition capsule; Fibres (Edible plant) [non-nutritive]; Injection; Raw material drug; Troche; suppository; Food preparations adapted for medical purposes; Dietetic foods adapted for medical purposes; Dietetic substances adapted for medical use

 

Humankind

   

7/21/2009 to 7/20/2019

 

 

 

   

   

   

 

“KDLK”

 

3230404

   

No.5 : Food preparations adapted for medical purposes; Dietetic foods adapted for medical purposes; Dietetic substances adapted for medical use

   

Humankind

   

9/28/2013 to 9/27/2023

 

 

 

   

   

   

 

“dr.xiao”

 

5176731

   

No.5 : Disinfectant; Medicines for veterinary purposes; Insecticide; Sanitary napkin; Medicine health bag; Dental lacquer

   

Humankind

   

8/14/2009 to 8/13/2019

 

 

 

   

   

   

 

“dr.xiao”

 

1610828

   

No.30: non-medicial nutrition liquid; non-medicial nutrition cream; non-medicial nutrition powder; Honey; non-medicial nutrition capsule; non-medicial nutrition gum; Candy for food; Spirulina (non-medicial nutrient); Candy; Pollen healthy grease

 

Humankind

   

7/28/2011 to 7/27/2021

 

 

 

   

   

   

 

“DaLeNing”

 

5053772

   

 No.5 : Medicine for human; Chinese patent drugs; Suppository; Tincture; Water aqua; Paste; Liniment; Medical lotion; Patch; Chemical pharmaceuticals preparations

   

 HLJ Huimeijia

   

5/7/2009 to 5/6/2019

 

16



“Xuedu”

 

5053657

 

 

No.5 : Medicine for human; Chinese patent drugs; Suppository; Tincture; Water aqua; Paste; Liniment; Medical lotion; Patch; Chemical pharmaceuticals preparations

 

 

HLJ Huimeijia

 

 

5/7/2009 to 5/6/2019

 

 

 

 

 

 

 

 

 

 

“Xuedu” with an image

 

642099

 

 

No.5 : Paste

 

 

HLJ Huimeijia

 

 

5/21/2013 to 5/20/2023

 

 

 

 

 

 

 

 

 

 

“Tai Yan Li”

 

10014001

 

 

No.30: Honey, spirulina (non-medical), non-medical nutrient solution, non-medical nutrient lotion, non-medical nutrient powder, non-medical nutrient capsule, pastry, cereal, flour product.

 

Humankind

 

 

11/28/2012 to 11/27/2022

 

 

 

 

 

 

 

 

 

 

“Tai Yan Li”

 

10013969

 

 

No. 3: Cleanser lotion, soup, anti -bacterial hand soup, cleanser, cosmetics, conditioning gel, polish, essential oil.

 

 

Humankind

 

 

11/28/2012 to 11/27/2022

 

 

 

 

 

 

 

 

 

 

“Luo Qian’

 

8358643

 

 

No. 3: essential oil, fragrance essential oil, nourishing essential oil, cosmetic mask, cosmetic tools, cosmetics, cosmetic cleanser, perfume, weight-losing cosmetics, banishing essence.

 

 

Humankind

 

 

6/14/2011 to 6/13/2021

 

(1) The trademarks listed here have been spelt in Pinyin for the U.S. readers’ convenience. The original trademarks are in Chinese characters.

(2) The Company is applying for new valid term. Each trademark will be granted a six-month extension period for applying new valid term.

In addition, the trademark of “LB” and its associated image under the registration number 1738881 was transferred from Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd to us on March 19, 2015, from whom we acquired 12 health products in January 2013.

We have the right to use the following patents under the approval of National Bureau of Intellectual Property:

 

 

 

 

 

 

 

 

 

Patent

 

Categories

 

Name

 

 

Inventor/Designer

 

 

Patent No.

 

 

Duration

 

 

Owner

 

 

 

 

 

 

 

 

 

 

 

Invention Patent

 

Runchao Soft Capsule and Its Manufacturing Method

 

 

Xin Sun

 

 

ZL200610010394.4

 

 

August 10, 2006-
August 9, 2026

 

 

Xin Sun*

 

 

 

 

 

 

 

 

 

 

 

Utility Patent

 

Heating System in Compression Coaster with Coating Wheels

 

 

ZhengJiang Huang

 

 

ZL201220485432.2

 

 

September 22, 2012-
September 21, 2022

 

 

HLJ Huimeijia

 

 

 

 

 

 

 

 

 

 

 

Design Patent

 

Packing Box for Pain- relieving Ointment

 

 

Jianjun Wang

 

 

ZL201230448116.3

 

 

September 19, 2012-
September 18, 2022

 

 

HLJ Huimeijia

 

17



Design Patent

 

Packing Box for Nasal Mucus-releiving Ointment

 

 

Jianjun Wang

 

 

ZL201230448676.9

 

 

September 19, 2012-
September 18, 2022

 

 

HLJ Huimeijia

 

 

 

 

 

 

 

 

 

 

 

Design Patent

 

Packing Box for Gou Pi Plaster

 

 

Jianjun Wang

 

 

ZL201230447952.X

 

 

September 19, 2012-
September 18, 2022

 

 

HLJ Huimeijia

 

 

 

 

 

 

 

 

 

 

 

Design Patent

 

Packing Box for Tendons and Bones Strengthening Musk Ointment

 

 

Jianjun Wang

 

 

ZL201230448670.1

 

 

September 19, 2012-
September 18, 2022

 

 

HLJ Huimeijia

 

 

 

 

 

 

 

 

 

 

 

Design Patent

 

Packing Box for Pain- relieving Musk Ointment

 

 

Jianjun Wang

 

 

ZL201230448010.3

 

 

September 19, 2012-
September 18, 2022

 

 

HLJ Huimeijia

 

*Mr. Sun verbally authorized the Company the right to use the patent.

The laws governing our business are as follows:

 

Pharmaceutical administration law of the PRC enacted January 12, 2001

     

 

Healthcare registration and administration law, enacted January 7, 2005

     

 

Measures for the Administration of Pharmaceutical Trade License, enacted January 4, 2004

     

Measures for the Supervision Over and Administration of Pharmaceutical Production, enacted May 8, 2004

     

 

Food Safety Law of the PRC, enacted June 1, 2009

     

 

Regulation on the Implementation of the Food Safety Law of the PRC, enacted July 20, 2009

     

Regional regulation: Heilongjiang Regional Medicinal Materials Resource Protection Bylaw, enacted January 8, 2005

     

 

Good Manufacturing Practice (GMP) Amendment, enacted January 17, 2011

In the PRC, a Good Manufacturing Practice Certification (“GMP Certification”) is required for companies that produce medical drugs and health supplements. It is also required to market our medical drugs and health supplements. According to the Administrative Rules of Drug Manufacturing and Certification issued by the CFDA of the PRC on September 7, 2005, the CFDA is responsible for the review and issuance of GMP Certification. To obtain a GMP Certification, a company shall submit its application; the CFDA will then conduct a technical review of the application materials; if such company passes the technical review, the CFDA will inspect the manufacturing site. The CFDA also conducts follow-up inspections on the manufacturing site. After the issuance of the GMP Certification, the CFDA may inspect the manufacturing site from time to time. The GMP Certifications of our wholly owned subsidiaries, Humankind, HLJ Huimeijia and Huimeijia, are valid through February 14, 2019, December 31, 2015, and July 22, 2014, respectively. For the GMP Certificate of HLJ Huimeijia’s, the Company has applied a new certificate, which is expected to be issued in April 2017. Once GMP Certification is obtained, we would be able to manufacture and market our products without further governmental approval. For the GMP Certificate of Huimeijia’s, the Company did not renew the GMP Certificate due to its pending assets sale to Xiuzheng Pharmacy.

18


Employees

As of June 30, 2016, we have 95 employees including 8 officers, 33 administrators, 32 sales persons and 22 workers in manufacturing. We believe that we are in compliance with local prevailing wage, contractor licensing and insurance regulations, and have good relations with our employees.

We also have 19 independent workers for packing.

Item 1A. Risk Factors.

We are a smaller reporting company and therefore this item is not applicable to us.

Item 1B. Unresolved Staff Comments.

Not applicable.

Item 2. Properties.

All land belongs to the state in PRC. Enterprises and individuals can pay the state a fee to obtain a right to use a piece of land for commercial purpose or residential purpose for an initial period of 50 years or 70 years, respectively. The land use right can be sold, purchased, and exchanged in the market. The land use right of a successor owner will be reduced by the amount of time consumed by the predecessor owner.

We manufacture our products on a plot of land located in Jin Xing Industrial Park, Songbei District, Harbin. On June 7, 2004, the Company entered into a Land Use Purchase Contract with the local government, pursuant to which the Company agreed to purchase the right to use a piece of land, approximately 8 acres (32,000 square meters), located in Harbin County, Heilongjiang Province for commercial purposes for a fifty-year period from June 7, 2004 through June 6, 2054, for $637,261 (RMB 5,248,000). The Company has fully paid to the government the consideration for the land use right on June 13, 2004. The Department of Housing and Urban Development of Harbin City approved this transaction. The Company is in the process of applying for the title certificate from the local government. Due to certain re-zoning conducted by the local government, the estimate time to receive the title certificate is uncertain. The Company is thriving to accelerate the process. The manufacturing facility on the land is 4,000 square meters and there are five production lines which are sufficient for our operation. We package our products in bottles, plastic containers and aluminum foil bags.

After we acquired HLJ Huimeijia on November 22, 2013, we also manufacture our medicines and drugs using HLJ Huimeijia’s land, approximately 43,350 square meters, located in Hai-lin Economic Development Zone, Mudanjiang City. The manufacturing facilities occupy approximately 5,710 square meters. We plan to build new manufacturing facilities on the land. The expected construction cost is approximately $7,520,000 (RMB 50,000,000).

In addition, the building of HLJ Huimeijia in the book value of $1,796,166 has been mortgaged for the working capital loan in the principal amount of $1,611,967 (RMB 10,000,000).

Item 3. Legal Proceedings.

We do not know of any material, active, pending or threatened proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding or pending litigation.

Item 4. Mine Safety Disclosures.

This item is not applicable to us.

19


PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is traded over-the-counter on the OTC Markets QB Tier under the ticker “CHHE” and the market for the stock has been relatively inactive. The range of high and low bid quotations for the quarters of the last two years ended June 30, 2016 and 2015 for which financial statements are included is listed below. The quotations are taken from Yahoo Finance. They reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not necessarily represent actual transactions.

Calendar Quarter   High Bid     Low Bid  
             
Fiscal Year ended June 30, 2015            
First Quarter $  0.60   $  0.03  
Second Quarter $  0.18   $  0.11  
Third Quarter $  0.24   $  0.11  
Fourth Quarter $  0.20   $  0.15  
             
Fiscal Year ended June 30, 2016            
First Quarter $  0.23   $  0.10  
Second Quarter $  0.15   $  0.08  
Third Quarter $  0.40   $  0.05  
Fourth Quarter $  0.86   $  0.17  

As of September 14, 2016, we had approximately 496 shareholders of record of our common stock, such number of holders does not include street name holders who hold shares by brokerage firms. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of the common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.

Dividends

We have not paid dividends on our common stock and do not anticipate paying such dividends in the foreseeable future. We will rely on dividends from Humankind for our funds and PRC regulations may limit the amount of funds distributed to us from Humankind, which will affect our ability to declare any dividends.

Securities Authorized for Issuance Under Equity Compensation Plans

On March 27, 2015 the Board of Directors (the “Board”) adopted the Company’s 2015 Equity Incentive Plan (the “Plan”), which became effective as of such date. The total number of authorized shares under the Plan is 6,000,000 shares of common stock. For the material features of the Plan, please see Note 16.

The following table summarizes the number of shares of our common stock authorized for issuance under our the Plan as of June 30, 2016.

Equity Compensation Plan Information

          Number of securities  

          remaining available for  

          future issuance under  

  Number of securities to     Weighted-average     equity compensation  

  be issued upon exercise     exercise price of     plans (excluding  

  of outstanding options,     outstanding options,     securities reflected in  

Plan category

  warrants and rights (a)     warrants and rights (b)     column (a)) (c)  

Equity compensation plans approved by security holders

 

-

-

-

Equity compensation plans not approved by security holders

 

0

-

2,700,000

(1)

Total

 

20


(1) The Company granted an aggregate of 3.3 million shares of restricted shares to its CEO and an employee on March 30, 2015.

Registrar and Stock Transfer Agent

Our stock transfer agent is Interwest Transfer Company, Inc. at 1981 Murray Holladay Road, Suite 100 Salt Lake City, UT 84117. Their telephone number is (801)272-9294, and their fax number is (801) 277-3147.

Shares Eligible for Future Sale

There is no established trading market for our common stock. Future sales of substantial amounts of our common stock in the trading market could adversely affect market prices.

Penny Stock Regulations

Our shares of common stock are subject to the “penny stock” rules of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and various rules thereunder. In general terms, “penny stock” is defined as any equity security that has a market price less than $5.00 per share, subject to certain exceptions. The rules provide that any equity security is considered to be a penny stock unless that security is registered and traded on a national securities exchange meeting specified criteria set by the SEC, issued by a registered investment company, and excluded from the definition on the basis of price (at least $5.00 per share), or based on the issuer’s net tangible assets or revenues. In the last case, the issuer’s net tangible assets must exceed $3,000,000 if in continuous operation for at least three years or $5,000,000 if in operation for less than three years or the issuer’s average revenues for each of the past three years must exceed $6,000,000.

Trading in shares of penny stock is subject to additional sales practice requirements for broker-dealers who sell penny stocks to persons other than established customers and accredited investors. Accredited investors, in general, include individuals with assets in excess of $1,000,000 or annual income exceeding $200,000 (or $300,000 together with their spouse), and certain institutional investors. For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of the security and must have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, the rules require the delivery, prior to the first transaction, of a risk disclosure document relating to the penny stock. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, and current quotations for the security. Finally, monthly statements must be sent disclosing recent price information for the penny stocks. These rules may restrict the ability of broker-dealers to trade or maintain a market in our common stock, to the extent it is penny stock, and may affect the ability of shareholders to sell their shares.

Recent Sale of Unregistered Securities

On March 29, 2016, we issued 300,000 shares of Common Stock to our consultant as part of compensation for its services. The shares are restrictive with a standard legend under the Securities Act of 1933, as amended (the “Securities Act”). The issuance was in reliance upon the exemption afforded under Section 4(2) of the Securities Act. The shares had been returned to the Company, pending for procedures to finalize the cancellation. No other sales of unregistered securities were made in fiscal 2016.

Repurchase of Equity Securities

None.

Item 6. Selected Financial Data.

Not Applicable.

21



Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD LOOKING STATEMENTS

We make certain forward-looking statements in this report. Statements concerning our future operations, prospects, strategies, financial condition, future economic performance (including growth and earnings), demand for our services, and other statements of our plans, beliefs, or expectations, including the statements contained under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as captions elsewhere in this document, are forward-looking statements. In some cases, these statements are identifiable through the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would,” and similar expressions. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks, and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. These risks and uncertainties, together with the other risks described from time to time in reports and documents that we file with the SEC should be considered in evaluating forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. Indeed, it is likely that some of our assumptions will prove to be incorrect. Our actual results and financial position will vary from those projected or implied in the forward-looking statements and the variances may be material. You are cautioned not to place undue reliance on such forward-looking statements, which reflect our view only as of the date of this report.

Important factors that could cause actual results to differ from those in the forward-looking statements include, without limitation, the following:

  the effect of political, economic, and market conditions and geopolitical events;
     
  legislative and regulatory changes that affect our business;
     
  the availability of funds and working capital; and
     
  the actions and initiatives of current and potential competitors,

Except as required by applicable laws, regulations or rules, we do not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by any forward-looking statements.

The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes thereto as filed with the SEC and other financial information contained elsewhere in this report.

Except as otherwise indicated by the context, references in this report to “we,” “us,” “our,” “the Registrant,” “our Company,” or “the Company” are to China Health Industries Holdings, Inc., a Delaware corporation, China Health Industries Holdings Limited, a corporation incorporated under the laws of Hong Kong, its wholly owned subsidiary in China, Harbin Humankind Biology Technology Co. Limited (“Humankind”) and indirect 99% owned subsidiary, Harbin Huimeijia Medicine Company (“Huimeijia”) and indirect wholly owned subsidiary, Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”). Unless the context otherwise requires, all references to (i) “PRC” and “China” are to the People’s Republic of China; (ii) “U.S. dollar,” “$” and “US$” are to United States dollars; (iii) “RMB” are to Renminbi Yuan of China; (iv) “Securities Act” are to the Securities Act of 1933, as amended; and (v) “Exchange Act” are to the Securities Exchange Act of 1934, as amended.

22


Business Overview

Our principal business operations are conducted through our wholly-owned subsidiaries, Humankind and HLJ Huimeijia.

The Company owns a GMP-certified plant and facilities and has the capacity to produce 21 CFDA-approved medicines and 14 CFDA-approved health supplement products in soft capsule, hard capsule, tablet, granule and oral liquid forms. These products address the needs of some key sectors in China, including the feminine, geriatric and children’s markets.

HLJ Huimeijia's current certificate of GMP expired by the end of December 2015. HLJ Huimeijia has applied a new certificate of GMP, which is expected to be obtained in April 2017. However, there is no assurance that we will obtain the new GMP certificate by such time. According to the law of PRC, HLJ Huimeijia must cease all production activities before getting the new GMP certificate. The equipment and production line is being reconstructed from the third quarter of the fiscal year 2016 to the third quarter of the fiscal year 2017 for the purpose of applying for the new GMP certificate. Although HLJ Huimeijia could sell inventory produced before the expiration of its GMP certificate, management anticipates there will be no or very little revenue generated by HLJ Huimeijia during such a period.

Our business is conducted through our sales agents and sales personnel. We sell our products directly to end customers by our own sales personnel as well as our sales agents, operating primarily in Jiangsu, Zhejiang, Shanghai, Beijing, Anhui and Gansu, where most of our revenues are generated. Our sales through agents in Beijing, Zhejiang, Jiangsu and Shanghai provinces accounted for 12%, 11%, 11% and 10% of our total sales, respectively, for the year ended June 30, 2016. Although we do not currently sell our products online, we expect to do so in the future.

2017 Outlook

Overall, we anticipate our total revenues for the year ended June 30, 2017 versus the year ended June 30, 2016 to increase by 23% or approximately $1.8 million, with growth in all categories of our product sales, including the anticipated revenue from Humankind for approximately $9.3 million, mainly in the sales growth of Propolis and Black Ant Capsule, and from HLJ Huimeijia for approximately $0.3 million. The gross profit margin for the year ended June 30, 2017 is expected to be approximately 30%, and we estimate our overall net profit margin for the year ended June 30, 2017 to be approximately 10%. There is, however, no assurance that we will reach these projections.

Results of Operations

The following table summarizes the top lines of the results of our operations for the years ended June 30, 2016 and 2015, respectively:

    June 30, 2016     June 30, 2015     Variance     %  
Revenues $  7,816,501   $  10,226,052   $ (2,409,551 )   (23.56% )
   Humankind   7,113,023     8,656,245     (1,543,222 )   (17.83% )
   HLJ Huimeijia   703,478     1,569,807     (866,329 )   (55.19% )

Cost of Goods Sold

$  5,501,123   $  7,290,174   $ (1,789,051 )   (24.54% )
   Humankind   4,920,644     6,086,263     (1,165,619 )   (19.15% )
   HLJ Huimeijia   580,479     1,203,911     (623,432 )   (51.78% )
Gross Profit $  2,315,378   $  2,935,878   $  (620,500 )   (21.14% )
   Humankind   2,192,379     2,569,982     (377,603 )   (14.69% )
   HLJ Huimeijia   122,999     365,896     (242,897 )   (66.38% )

Revenue

Total revenues decreased by $2,409,551, or 23.56%, for the year ended June 30, 2016 as compared to the same period in 2015. The decrease in revenues was primarily due to a decrease of $1,543,222 or 17.83% in Humankind’s revenues and a decrease of $866,329 or 55.19% in HLJ Huimeijia’s revenues for the year ended June 30, 2016 as compared to the same period in 2015. The decrease of the sales revenue in Humankind was primarily due to the decrease in sales volume of Waterlilies Soft Capsule, which was caused by our shift of marketing focus from such product to Propolis and Black Ant Capsule. The decrease of the sales revenue in HLJ Huimeijia was primary due to the expiration of its GMP certificate on December 31, 2015. During the last three months prior to such an expiration date, HLJ Huimeijia reduced its production and marketing operation as more attention was paid to the preparation of manufacturing and technical improvement in order to meet the requirements for obtaining a new GMP certificate. Moreover, during the third quarter and fourth quarter of fiscal year 2016, HLJ Huimeijia ceased all production activities, reconstructed its equipment and production line for the purpose of applying for the new GMP certificate while selling inventory produced before the expiration of the GMP certificate.

23


Our total cost of sales decreased $1,789,051 or 24.54% for the year ended June 30, 2016 as compared to the same period in 2015. The decrease in cost of sales was primarily due to a decrease of $1,165,619 or 19.15% in Humankind’s cost of sales and a decrease of $623,432 or 51.78% in HLJ Huimeijia’s cost of sales for the year ended June 30, 2016 as compared to the same period in 2015, which were primarily due to the decrease in sales volume of Humankind and HLJ Huimeijia.

Our gross margin decreased $620,500 from $2,935,878 for the year ended June 30, 2015 to $2,315,378 for the year ended June 30, 2016. This decrease was due to the decrease in sales volume of Humankind and HLJ Huimeijia as discussed above. On the other hand, the new bonus packing of products with more units in one package were made by HLJ Huimeijia before the expiration of GMP certificate in order to adapt to the consumers’ changing preference, and the unit fixed production cost increased due to the decrease in total production output, while the total fixed cost includes equipment and plant depreciation and the salary of the production workers, most of which do not vary with production output. This led to higher unit cost and lower unit gross profit.

Sales by Product Line

The following table summarizes a breakdown of our sales by major product line for the years ended June 30, 2016 and 2015, respectively:

    June 30, 2016     June 30, 2015  
    Quantity           % of     Quantity           % of  
    (Unit)     Sales US$     Sales     (Unit)     Sales US$     Sales  
Humankind                                    
Waterlilies Soft Capsule (Sailuozhi)   64,323   $  4,089,058     52.31%     81,459   $  5,408,370     52.89%  
Propolis and Black Ant Capsule   105,370     3,023,965     38.69%     108,995     3,247,876     31.76%  
HLJ Huimeijia                                    
Muskiness Bone Strengthener Paste   991,399     259,431     3.32%     1,900,489     530,890     5.19%  
Muskiness Pain Relieving Paste   379,765     101,806     1.30%     748,259     224,284     2.19%  
Injury and Rheumatism relieving Paste   332,318     92,069     1.18%     730,511     200,400     1.96%  
Refining GouPi Cream   445,021     117,435     1.50%     968,856     256,856     2.51%  
Enema Glycerini   945,211     93,101     1.19%     1,546,057     154,746     1.51%  
Umguentum Acidi Borici Camphoratum   133,090     37,318     0.48%     194,747     62,186     0.61%  
Injury and Paralysis Tincture   -     -     0.00%     19,876     20,354     0.20%  
Pelvic Inflammation Suppository   -     -     0.00%     39,276     22,578     0.22%  
Indometacin and Furazolidone Suppositories   1,100     440     0.01%     101,540     52,359     0.51%  
Ge Hong Beriberi Water   6,480     1,878     0.02%     46,597     14,356     0.14%  
Hydrogen Peroxide Solution   -     -     0.00%     96,710     10,748     0.11%  
Triamcinolone Acetonide and                                    
Neomycin Paste   -     -     0.00%     292,350     20,049     0.20%  
Total       $  7,816,501     100.00%         $  10,226,052     100.00%  

Operating Expenses

The following table summarizes our operating expenses for the years ended June 30, 2016 and 2015, respectively:

24



   

June 30, 2016

    June 30, 2015     Variance     %  
Operating Expenses                        
Selling, general and administrative $  1,960,679   $  2,123,459   $  (162,780 )   (7.67% )
Depreciation and amortization   637,231     585,680     51,551     8.80%  
Total Operating Expenses $  2,597,910   $  2,709,139   $  (111,229 )   (4.11% )

Total operating expenses for the year ended June 30, 2016 decreased $111,229 or 4.11%, as compared to the corresponding period in 2015. The decrease in operating expenses was primarily attributable to a decrease of $162,780 or 7.67% in selling, general and administrative expenses, partly offset by an increase of $51,551 or 8.80% in depreciation and amortization expenses. The decrease in selling, general and administrative expenses was mainly due to the expiration of HLJ Huimeijia GMP certificate on December 31, 2015. During the six months ended June 30, 2016, HLJ Huimeijia ceased all production activities and reconstructed equipment and production line in order to apply for the new GMP certificate, which resulted in the decrease of selling, general and administrative expenses for the year ended June 30, 2016 as compared to the same period in 2015. The increase in depreciation and amortization expenses was primarily due to the reversed adjustment of land use right amortization in 2015 caused by an estimated useful life change.

Interest Income and Interest Expense

Interest income was $72,328 for the year ended June 30, 2016, as compared to $97,432 for the year ended June 30, 2015. This decrease of $25,104, or 25.77%, was primarily because the Company made certain investments which reduced the average balance of deposits in the bank compared with the same period last year.

Interest expense was $102,253 for the year ended June 30, 2016, a decrease of $23,355 or 18.59%, as compared to $125,608 for the year ended June 30, 2015. The decrease of interest expenses was mainly due to the decrease of short-term loan interest rate.

Income Taxes

Income taxes increased $109,081, or 46.44%, from $234,905 for the year ended June 30, 2015 to $343,986 for the year ended June 30, 2016. This was due to the increase in income before income taxes of one of the Company’s subsidiaries, Humankind, with an increase from $939,619 for the year ended June 30, 2015 to $1,375,943 for the same period of 2016.

Net Income and Income Per Share

Net income was $159,587 for the year ended June 30, 2016, as compared to net income of $2,509 for the year ended June 30, 2015. This increase of $157,078, or 6260.58% in net income was primarily attributable to the increase in investment income in the amount of $776,337, partially offset by a decrease in gross profit of $620,500 for the year ended June 30, 2016 as compared to the same period of 2015.

Income per share was $0.002 and $0.000 for the years ended June 30, 2016 and 2015, respectively. This increase was primarily a result of the above increase in net income.

Liquidity and Capital Resources

We believe our current working capital position, together with our expected future cash flows from operations, loans from our major shareholder, will be adequate to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for at least the next twelve months. However, this belief is based upon many assumptions and is subject to numerous risks, and there can be no assurance that we will not require additional funding in the future.

The following table summarizes our cash and cash equivalents position, our working capital, and our cash flow activity as of June 30, 2016 and 2015 and for the years ended June 30, 2016 and 2015:

25



  2016     2015  
As of June 30:            
Cash and cash equivalents $  29,791,730   $  21,123,027  
Working capital $  25,518,206   $  26,409,788  
Inventories $  419,987   $  841,239  

    2016     2015  
For the years ended June 30:            
Cash provided by (used in):            
Operating activities $  1,888,414   $  2,142,140  
Investing activities $  7,610,748   $  (8,682,581 )
Financing activities $  908,536   $  403,180  

Cash and cash equivalents increased $8,668,703 from $21,123,027 as of June 30, 2015 to $29,791,730 as of June 30, 2016, primarily attributable to net cash provided by operating activities in the amount of $1,888,414, net cash provided by investing activities in the amount of $7,610,748 and net cash provided by financing activities in the amount of $908,536, offset by the negative effect of prevailing exchange rates on our cash position of $1,738,995.

Our working capital at June 30, 2016 was $25,518,206, compared to working capital of $26,409,788 at June 30, 2015. This decrease of $891,582 or 3.38% was primarily attributable to the increase in related party debts in the amount of $802,860.

Net cash provided by operating activities was $1,888,414 for the year ended June 30, 2016, primarily attributable to the net income available to the Company in the amount of $159,602, the depreciation and amortization expenses of $755,739 and share based compensation of $225,000 as reconciled, and the decrease in accounts receivable of $186,198, the decrease in inventory of $209,870 and the increase in taxes payable of $310,572.

Net cash provided by investing activities was $7,610,748 for the year ended June 30, 2016, primarily due to the recouping of short-term investment in the amount of $7,763,372.

Net cash provided by financing activities was $908,536 for the year ended June 30, 2016, attributable to the collections of related party debts in the amount of $955,893, offset by the repayment of related party debts in the amount of $47,357. The negative effect of exchange rate changes on cash and cash equivalents in the amount of $1,738,995 for the year ended June 30, 2016 was mainly a result of the effect of the devaluation of the RMB to the USD on the significant amount of cash and cash equivalents held by the Company in RMB. The exchange rates from USD to RMB were 6.6459 to 1 and 6.2000 to 1 as of June 30, 2016 and 2015, respectively, and the average exchange rates from USD to RMB were 6.4405 to 1 and 6.1875 to 1 for the years ended June 30, 2016 and 2015, respectively.

Other than as described in this report, we have no present agreements or commitments with respect to any material acquisitions of businesses, products, product rights or technologies or any other material capital expenditures. However, we will continue to evaluate acquisitions of, and/or investments in, products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. Accordingly, we may need to obtain additional sources of capital in the future to finance any such acquisitions and/or investments. We may not be able to obtain such financing on commercially reasonable terms, if at all. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.

Related Party Debts

We had related party debts of $2,713,406 as of June 30, 2016, as compared to $1,910,546 as of June 30, 2015, an increase of $802,860 or 42.02% . The amount of related party debts mainly consists of a loan from Mr. Xin Sun, the CEO of the Company. The loan is unsecured and non-interest bearing and has no fixed terms of repayment. There was no written agreement for the loan. See Note 10.

26


Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our financial position or results of operations.

Critical Accounting Policies and Estimates

Management's discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with US GAAP. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 2 to our consolidated financial statements, “Significant Accounting Policies”, is incorporated herein by reference.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

Not Applicable.

Item 8. Financial Statements and Supplementary Data.

The financial statements required by this item are set forth beginning on page F-1.

27


INDEX TO CONSOLIDATED AND COMBINED STATEMENTS

Audited Consolidated and Combined Financial Statements:

Reports of Independent Registered Public Accounting Firm

Consolidated and Combined Balance Sheets as of June 30, 2016 and 2015

Consolidated and Combined Statements of Operations and Comprehensive Income For the Years Ended June 30, 2016 and 2015

Consolidated and Combined Statements of Equity For the Years Ended June 30, 2016 and 2015

Consolidated and Combined Statements of Cash Flows For the Years Ended June 30, 2016 and 2015

Notes to Consolidated and Combined Financial Statements

28


CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Audited)

    June 30, 2016     June 30, 2015  
ASSETS            
             
Current assets            
     Cash and cash equivalents $  29,791,730   $  21,123,027  
     Short term investment   -     8,064,516  
     Notes receivable   -     1,509  
     Accounts receivable, net   1,145,131     1,431,298  
     Inventory   419,987     841,239  
     Other receivables, net   35,484     39,852  
     Advance to suppliers   154,988     69,120  
Total current assets   31,547,320     31,570,561  
             
Property, plant and equipment, net   3,868,561     4,315,094  
Intangible assets, net   4,191,059     5,012,297  
Construction in progress   671,857     607,477  
Total assets $  40,278,797   $  41,505,429  
             
LIABILITIES AND EQUITY            
             
Current liabilities            
     Short-term loans $  1,504,687   $  1,612,903  
     Accounts payable and accrued expenses   487,730     523,946  
     Other payables   37,052     29,684  
     Advance from customers   645,622     770,454  
     Related party debts   2,713,406     1,910,546  
     Wages payable   173,004     134,615  
     Taxes payable   467,613     178,625  
Total current liabilities   6,029,114     5,160,773  
             
Equity            
     Common stock, ($0.0001 par value, 300,000,000 shares authorized, 
     65,839,737 and 65,539,737 issued and outstanding as of June 30, 2016 and 2015, respectively)
  6,554     6,404  
     Additional paid-in capital   521,987     297,137  
     Accumulated other comprehensive income   784,045     3,263,592  
     Statutory reserve   38,679     38,679  
     Retained earnings   32,898,244     32,738,642  
Total stockholders' equity   34,249,509     36,344,454  
Non-controlling interests   174     202  
Total equity   34,249,683     36,344,656  
             
Total liabilities and equity $  40,278,797   $  41,505,429  

The accompanying notes are an integral part of these consolidated and combined financial statements.

F-3


CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Audited)

    For the Year Ended  
    June 30, 2016     June 30, 2015  
             
REVENUE $  7,816,501   $  10,226,052  
             
COST OF GOODS SOLD   5,501,123     7,290,174  
             
GROSS PROFIT   2,315,378     2,935,878  
             
OPERATING EXPENSES            
     Selling, general and administrative expenses   1,960,679     2,123,459  
     Depreciation and amortization expenses   637,231     585,680  
          Total operating expenses   2,597,910     2,709,139  
             
INCOME (LOSS) FROM OPERATIONS   (282,532 )   226,739  
             
OTHER INCOME/(EXPENSES)            
     Interest income   72,328     97,432  
     Interest expense   (102,253 )   (125,608 )
     Investment income   776,337     -  
     Other income, net   39,693     38,851  
          Total other income, net   786,105     10,675  
             
INCOME BEFORE INCOME TAXES   503,573     237,414  
             
Provision for income taxes   343,986     234,905  
             
NET INCOME   159,587     2,509  
Less: net loss attributable to non-controlling interests   (15 )   (52 )
Net income attributable to China Health Industries Holdings   159,602     2,561  
Foreign currency translation gain (loss)   (2,479,560 )   20,582  
             
Comprehensive income (loss)   (2,319,973 )   23,091  
Less: comprehensive income (loss) attributable to non-controlling interests   (28 )   51  
             
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO CHINA HEALTH INDUSTRIES HOLDINGS $  (2,319,945 ) $  23,040  
             
Net income attributable to China Health Industries Holdings' shareholders per share are:        
     Basic & diluted loss per share $  0.002   $  0.000  
             
Weighted average shares outstanding:            
     Basic & diluted weighted average shares outstanding   65,616,175     63,044,395  

The accompanying notes are an integral part of these consolidated and combined financial statements.

F-4


CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Audited)

                                  Accumulated                    
    Common Shares     Additional                 Other     Total     Non-        
                Paid-in     Retained     Statutory     Comprehensive     Stockholders'     controlling     Total  
    Shares     Amount     Capital     Earnings     Reserve     Income (loss)     Equity     Interest     Equity  
                                                       
Balance, June 30, 2014 62,239,737 $ 6,224 27,317 $ 32,736,081 38,679 $ 3,242,959 $ 36,051,260 $ 253 $ 36,051,513
                                                       
 Net income   -     -     -     2,509     -     -     2,509     -     2,509  
                                                       
Accrued compensation expense for vested shares   3,300,000     180     -     -     -     -     180     -     180  
                                                       
Additional paid in capital   -     -     269,820     -     -     -     269,820     -     269,820  
                                                       
Other comprehensive loss - Translation adjustment   -     -     -     52     -     20,633     20,685     (51 )   20,634  
                                                       
Balance, June 30, 2015   65,539,737   $  6,404   $  297,137   $  32,738,642   $  38,679   $  3,263,592     36,344,454     202     36,344,656  
                                                       
Net income (loss)   -     -     -     159,602     -     -     159,602     (15 ) $  159,587  
                                                       
Accrued compensation expense for vested shares   300,000     150     224,850     -     -     -     225,000     -     225,000  
                                                       
Other comprehensive loss - Translation adjustment   -     -     -     -     -     (2,479,547 )   (2,479,547 )   (13 )   (2,479,560 )
                                                       
Balance, June 30, 2016   65,839,737   $  6,554   $  521,987   $  32,898,244   $  38,679   $  784,045   $  34,249,509   $  174   $  34,249,683  

The accompanying notes are an integral part of these consolidated and combined financial statements.

F-5


CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Audited)

    For the Year Ended  
    June 30, 2016     June 30, 2015  
Cash Flows from Operating Activities            
     Net loss available to China Health Industries Holdings $  159,602   $  2,561  
     Adjustments to reconcile net income to net cash provided by operating activities:            
           Depreciation and amortization expenses   755,739     814,941  
           Provision for doubtful accounts   34,957     -  
           Provision for inventories   164,859     -  
           Non-controlling interests   (15 )   (52 )
           Share based compensation   225,000     -  
     Changes in operating assets and liabilities            
           Accounts receivable   186,198     802,366  
           Other receivables   950     43,855  
           Inventory   209,870     197,703  
           Advance to suppliers and prepaid expenses   (141,197 )   73,580  
           Accounts payables and accrued expenses   (1,240 )   (103,735 )
           Advance from customers and other payables   (65,815 )   471,798  
           Wages payable   48,934     65,161  
           Taxes payable   310,572     (226,038 )
     Net cash provided by operating activities   1,888,414     2,142,140  
             
Cash Flows from Investing Activities            
           Increase in short term investment   -     (8,080,845 )
           Recouping of short term investment   7,763,372     -  
           Decrease in notes receivable   1,453     26,656  
           Purchases of property, plant and equipment   (93,304 )   (21,624 )
           Increase in construction in progress   (60,773 )   (606,768 )
     Net cash provided by (used in) investing activities   7,610,748     (8,682,581 )
             
Cash Flows from Financing Activities            
           Compensation for vested shares   -     180  
           Collection of related party debts   955,893     650,354  
           Repayment of related party debts   (47,357 )   (517,174 )
           Capital contributed by non-controlling interest owner   -     269,820  
     Net cash provided by financing activities   908,536     403,180  
             
Effect of exchange rate changes on cash and cash equivalents   (1,738,995 )   28,214  
             
Net increase (decrease) in cash and cash equivalents   8,668,703     (6,109,047 )
             
Cash and cash equivalents, beginning balance   21,123,027     27,232,074  
             
Cash and cash equivalents, ending balance $  29,791,730   $  21,123,027  
             
Supplemental cash flow information            
     Cash paid for income taxes $  346,183   $  336,058  
     Cash paid for interest expense $  102,253   $  125,608  
             
Non-cash activities:            
     Loan from related party for the construction of a facility $  473,566   $  492,932  

The accompanying notes are an integral part of these consolidated and combined financial statements.

F-6


CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND

China Health Industries Holdings, Inc. (“China Health US”) was incorporated in the State of Arizona on July 11, 1996 and was the successor of the business known as Arizona Mist, Inc. which began in 1989. On May 9, 2005, it entered into a Stock Purchase Agreement and Share Exchange (effecting a reverse merger) with Edmonds 6, Inc. (“Edmonds 6”), a Delaware corporation, and changed its name to Universal Fog, Inc. Pursuant to this agreement, Universal Fog, Inc. (which has been in continuous operation since 1996) became a wholly-owned subsidiary of Edmonds 6.

China Health Industries Holdings Limited (“China Health HK”) was incorporated on July 20, 2007 in Hong Kong under the Companies Ordinance as a limited liability company. China Health HK was formed for the purpose of seeking and consummating a merger or acquisition with a business entity organized as a private corporation, partnership, or sole proprietorship as defined by FASB ACS Topic 915 (“Development Stage Entities”).

Harbin Humankind Biology Technology Co., Limited (“Humankind”) was incorporated in Harbin City, Heilongjiang Province, the People’s Republic of China (the “PRC”) on December 14, 2003, as a limited liability company under the Company Law of the PRC. Humankind is engaged in the manufacturing and sale of health products.

On August 20, 2007, the sole shareholder of China Health HK entered into a share purchase agreement (the “Share Purchase Agreement”) with the owners of Humankind. Pursuant to the Share Purchase Agreement, China Health HK purchased 100% of the ownership in Humankind for a cash consideration of $60,408 (the “Share Purchase”). Subsequent to the completion of the Share Purchase, Humankind became a wholly-owned subsidiary of China Health HK. The Share Purchase was accounted for as a “reverse merger” since the owner of Humankind owned a majority of the outstanding shares of China Health HK’s common stock immediately following the execution of the Share Purchase Agreement, it was deemed to be the acquirer in the reverse merger. Consequently, the assets and liabilities and the historical operations that have been reflected in the financial statements for periods prior to the Share Purchase are those of Humankind and have been recorded at the historical cost basis. After completion of the Share Purchase, China Health HK’s consolidated financial statements include the assets and liabilities of both China Health HK and Humankind, the historical operations of Humankind, and the operations of China Health HK and its subsidiaries from the closing date of the Share Purchase.

F-7


On October 14, 2008, Humankind set up a 99% owned subsidiary, Harbin Huimeijia Medicine Company (“Huimeijia”), with its primary business being manufacturing and distributing medicine. Mr. Xin Sun, the Company’s majority owner, owns 1% of Huimeijia. Huimeijia is consolidated in the consolidated financial statements of China Health HK.

On December 31, 2008, China Health HK entered into a reverse merger with Universal Fog, Inc., a U.S. publicly traded shell company (the “Transaction”). China Health HK is the acquirer in the Transaction, and the Transaction has been treated as a recapitalization of China Health US. After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US. On April 7, 2009, Mr. Sun transferred 28,200,000 shares of common stock to 296 individuals, leaving him with 33,003,088 shares of common stock of China Health US, or approximately 53.03% of the total outstanding shares of common stock. Universal Fog, Inc. changed its name to China Health Industries Holdings, Inc. on February 19, 2009.

On November 22, 2013, Humankind completed the acquisition of Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”) for a total purchase price of $16,339,869 (RMB100,000,000). HLJ Huimeijia was founded on October 30, 2003, and is engaged in the manufacturing and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. HLJ Huimeijia’s predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which has established its brand name in the market through its supply of high quality medical products. HLJ Huimeijia is categorized as a “high and new technology” enterprise by the Science Technology Department in Heilongjiang Province. HLJ Huimeijia has 21 products which have been approved by, and have received approval numbers issued by, the China State Food and Drug Administration (the “CFDA”). In addition, HLJ Huimeijia is the holder of one patent for utility models, five patents for external design and three trademarks in China, including the Chinese brand name of “Xue Du” which has an established reputation among customers in northeastern China.

China Health US, China Health HK, Humankind, Huimeijia and HLJ Huimeijia are collectively referred herein to as the “Company.”

As of June 30, 2016, the Company’s corporate structure was as follows:

F-8


F-9


Note 2 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the United States ("US GAAP") and have been consistently applied in the preparation of the consolidated financial statements.

Principles of Consolidation

The accompanying consolidated financial statements include China Health US and its four subsidiary companies, including China Health HK, Humankind, Huimeijia, and HLJ Huimeijia. All significant intercompany balances and transactions have been eliminated in consolidation and combination.

On November 22, 2013, China Health US, through its wholly owned subsidiary Humankind, completed the acquisition of HLJ Huimeijia. HLJ Huimeijia and Humankind are under the common control of Mr. Xin Sun, the CEO of the Company before and after the date of transfer. Humankind’s accounting policy adopted the guidance in ASC 805-50-05-5 for the transfer of net assets between entities under common control to apply a method similar to the pooling-of-interests method. Under this method, the financial statements of Humankind shall report results of operations for the period in which the transfer occurs as though the transfer of net assets had occurred at the beginning of the period. Results of operations for that period will thus comprise both those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. Similarly, Humankind shall present the statements of financial position and other financial information as of the beginning of the period as though the assets and liabilities had been transferred at that date. Financial statements and financial information of Humankind presented for prior years also shall be retrospectively adjusted to furnish comparative information.

Segment Reporting

FASB ASC Topic 280, “Segment Reporting,” established standards for reporting information about operating segments on a basis consistent with the Company's internal organizational structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Company's business segments. The Company has three reportable operating segments: Humankind, HLJ Huimeijia and others. The segments are grouped based on the types of products provided.

F-10


Fair Value of Financial Instruments

The provisions of accounting guidance, FASB ASC Topic 820 that applies to the Company requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

Fair Value Measurements

FASB ASC Topic 820, “Fair Value Measurements and Disclosures, ”clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.

Various inputs are considered when determining the fair value of the Company’s debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.

Level 1 –observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2 –other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).

Level 3 –significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets or liabilities carried and measured on a recurring basis during the reporting periods.

F-11


The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.

Translation of Foreign Currencies

Humankind, Huimeijia and HLJ Huimeijia maintain their books and accounting records in PRC currency “Renminbi” (“RMB”), which has been determined as the functional currency. Transactions denominated in currencies other than RMB are translated into RMB at the exchange rates prevailing on the date of the transactions, as quoted by the Federal Reserve Board. Foreign currency exchange gains and losses resulting from these transactions are included in operations.

Humankind, Huimeijia and HLJ Huimeijia’s financial statements are translated into the reporting currency, the United States Dollar (“USD”). Assets and liabilities of the above entities are translated at the prevailing exchange rate at each reporting period end date. Contributed capital accounts are translated using the historical rate of exchange when capital is injected. Income and expense accounts are translated at the average rate of exchange during the reporting period. Translation adjustments resulting from the translation of these financial statements are reflected as accumulated other comprehensive income in shareholders’ equity and non-controlling interests.

Statement of Cash Flows

In accordance with Statement FASB ASC Topic 230, “Statement of Cash Flows,” cash flow from the Company's operations is calculated based upon the local currencies and translated to the reporting currency using an average foreign exchange rate for the reporting period. As a result, amounts related to assets and liabilities reported in the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with US GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Significant estimates and assumptions by management include, among others; useful lives of long-lived assets and intangible assets, valuation of inventory, accounts receivable and notes receivable, impairment analysis of long-lived assets, construction in progress, intangible assets and deferred taxes. While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.

F-12


Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less at the time of purchase.

As of June 30, 2016 and 2015, the Company’s uninsured bank balance was mainly maintained at financial institutions located in the PRC and HK, totaled $29,791,730 and $21,123,027 respectively. The Company has no insured bank balance as of June 30, 2016 and 2015, respectively.

Accounts Receivable

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by performing credit checks and actively pursuing past due accounts. An allowance for doubtful accounts is established and determined based on management’s assessment of known requirements, aging of receivables, payment and bad debt history, the customer’s current credit worthiness, changes in customer payment patterns and the economic environment. From November 1, 2013, the Company changed its credit policy by offering ninety (90) day payment terms for sales agents, whereas the payment terms for sales agents before November 1, 2013 were thirty (30) day. As of June 30, 2016 and 2015, the balances of accounts receivable were $1,145,131 and $1,431,298, respectively. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company evaluated the nature of all accounts receivable then provided allowance for doubtful accounts. As of June 30, 2016 and 2015, the balances of allowance for doubtful accounts were $52,129 and $45,489, respectively.

F-13


Advance to Suppliers

The Company periodically makes advances to certain vendors for purchases of raw materials, or service providers for services relating to construction plans for our plant, equipment and production lines for the GMP upgrading, and records these payments as advance to suppliers. As of June 30, 2016 and 2015, advance to suppliers amounted to $154,988 and $69,120, respectively.

Inventory

Inventory consists of raw materials, work in progress and finished goods of manufactured products.

Inventory is stated at lower of cost or market and consists of materials, labor and overhead. HLJ Huimeijia uses the weighted average method for inventory valuation. The other entities of the Company use the first-in, first-out (“FIFO”) method for inventory valuation. Overhead costs included in finished goods include direct labor cost and other costs directly applicable to the manufacturing process. The Company evaluates inventory for excess, slow moving, and obsolete inventory as well as inventory the value of which is in excess of its net realizable value. This evaluation includes analysis of sales levels by product and projections of future demand. If future demand or market conditions are less favorable than the Company’s projections, a write-down of inventory may be required, and would be reflected in cost of goods sold in the period the revision is made. The inventory allowance with an amount of $164,859 and nil were provided for the years ended June 30, 2016 and 2015, respectively.

Impairment of Long-Lived Assets

The Company’s long-lived assets and other assets are reviewed for impairment in accordance with the guidance of the FASB ASC Topic 360-10, “Property, Plant, and Equipment,” and FASB ASC Topic 205, “Presentation of Financial Statements.” The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of the asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on the Company’s reporting results and financial position. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. As of June 30, 2016 and 2015, the Company has not experienced impairment losses on its long-lived assets. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.

F-14


Property, Plant and Equipment

Property, plant and equipment are carried at the lower of cost or fair value. Maintenance, repairs and minor renewals are expensed as incurred, major renewals and improvements that extend the lives or increase the capacity of plant assets are capitalized.

When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in the results of operations in the reporting period of disposition.

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets. The depreciable lives applied are:

  Building, Warehouse and Improvements 20 to 30 years
  Office Equipment 3 to 7 years
  Vehicles 5 to15 years
  Machinery and Equipment 7 to 15 years

Intangible Assets

The Company evaluates intangible assets in accordance with FASB ASC Topic 350, “Intangibles — Goodwill and Other.” Intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment tests. If the assumptions and estimates used to allocate the purchase price are not correct, or if business conditions change, purchase price adjustments or future asset impairment charges could be required. The value of the Company’s intangible assets could be impacted by future adverse changes such as: (i) any future declines in the Company’s operating results, (ii) a decline in the valuation of technology, including the valuation of the Company’s common stock, (iii) a significant slowdown in the worldwide economy, or (iv) any failure to meet the performance projections included in the Company’s forecasts of future operating results. In accordance with FASB ASC Topic 350, the Company tests intangible assets for impairment on an annual basis or more frequently if the Company believes indicators of impairment exist. Impairment evaluations involve management estimates of asset useful lives and future cash flows. Significant management judgment is required in the forecasts of future operating results that are used in the evaluations. It is possible, however, that the plans and estimates used may be incorrect. If the Company’s actual results, or the plans and estimates used in future impairment analysis, are lower than the original estimates used to assess the recoverability of these assets, we could incur additional impairment charges in a future period. Based on such evaluations, there was no impairment recorded for intangible assets for the years ended June 30, 2016 and 2015, respectively.

F-15


Construction in Progress

Construction in progress represents the costs incurred in connection with the construction of buildings or new additions to the Company’s plant facilities. Costs classified as construction in progress include all costs of obtaining the asset and bringing it to the location and condition necessary for its intended use. No depreciation is provided for construction in progress until such time as the assets are completed and are placed into service.

The Company reviews the carrying value of construction in progress for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, there was no impairment recorded for construction in progress for the years ended June 30, 2016 and 2015, respectively.

Translation of Foreign Currencies

Humankind, Huimeijia and HLJ Huimeijia maintain their books and accounting records in PRC currency “Renminbi” (“RMB”), which has been determined as the functional currency. Transactions denominated in currencies other than RMB are translated into RMB at the exchange rates prevailing on the date of the transactions, as quoted by the Federal Reserve Board. Foreign currency exchange gains and losses resulting from these transactions are included in operations.

Humankind, Huimeijia and HLJ Huimeijia’s financial statements are translated into the reporting currency, the United States Dollar (“USD”). Assets and liabilities of the above entities are translated at the prevailing exchange rate at each reporting period end date. Contributed capital accounts are translated using the historical rate of exchange when capital is injected. Income and expense accounts are translated at the average rate of exchange during the reporting period. Translation adjustments resulting from the translation of these financial statements are reflected as accumulated other comprehensive income in shareholders’ equity and non-controlling interests.

F-16


Revenue Recognition

The Company recognizes revenue when it is both earned and realized or realizable. The Company’s policy is to recognize revenue when title to the product, ownership and risk of loss have transferred to the customer, persuasive evidence of an arrangement exits and collection of the sales proceeds is reasonably assured, all of which generally occur upon shipment of goods to customers. The majority of the Company’s revenue relates to the sale of inventory to customers, and revenue is recognized when title and the risks and rewards of ownership pass to the customer. Given the nature of the Company’s business and the applicable rules guiding revenue recognition, the Company’s revenue recognition practices do not contain estimates that materially affect the results of operations. The Company records revenue at the discounted selling price and allows its customers to return products for exchange or credit subject to certain limitations. A provision for such returns is recorded based upon historical experience. There has been no provision recorded for returns based upon historical experience for the years ended June 30, 2016 and 2015, respectively.

Cost of Goods Sold

Cost of goods sold consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead costs associated with the manufacturing process and commission expenses.

Income Taxes

The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

In July 2006 the FASB issued FIN 48(ASC 740-10), “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB Statement No. 109 (ASC 740),” which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

F-17


As a result of the implementation of FIN 48 (ASC 740-10), the Company undertook a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or stockholders’ equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s financial statements.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from the Company’s estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

Enterprise Income Tax

Under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC (the “EIT Law”), income tax is payable by enterprises at a rate of 25% of their taxable income.

Value Added Tax

The Provisional Regulations of PRC Concerning Value Added Tax promulgated by the State Council came into effect on January 1, 1994. Under these regulations and the Implementing Rules of the Provisional Regulations of the PRC Concerning Value Added Tax, value added tax (“VAT”) is imposed on goods sold in, or imported into, the PRC and on processing, repair and replacement services provided within the PRC.

VAT payable in the PRC is charged on an aggregated basis at a rate of 13% or 17% (depending on the type of goods involved) on the full price collected for the goods sold or, in the case of taxable services provided, at a rate of 17% on the charges for the taxable services provided, but excluding, in respect of both goods and services, any amount paid in respect of VAT included in the price or charges, and less any deductible VAT already paid by the taxpayer on purchases of goods and services in the same financial year. As of June 30, 2016 and 2015, VAT payables were $183,813 and $219,553, respectively.

F-18


Sales-Related Taxes

Pursuant to the tax law and regulations of the PRC, the Company is obligated to pay 7% and 5% of the annual VAT paid as taxes on maintaining and building cities and education additional fees, both of which belong to sales-related taxes. Sales-related taxes are recorded when sales revenue is recognized. Sales-related taxes for the years ended June 30, 2016 and 2015 were $144,420, and $143,987, respectively.

Concentrations of Business and Credit Risks

All of the Company’s manufacturing is located in the PRC. There can be no assurance that the Company will be able to successfully continue to manufacture its products and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, prices of raw materials, competition, governmental and political conditions, and changes in regulations. Since the Company is dependent on trade in the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to the risks of restrictions on transfer of funds, domestic customs, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.

The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting periods.

Earnings Per Share

Basic earnings per common share is computed by dividing net earnings applicable to common shareholders by the weighted-average number of common shares outstanding during the period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. For the years ended June 30, 2016 and 2015, the Company had no potential dilutive common stock equivalents outstanding.

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

F-19


FASB ASC Topic 260, “Earnings Per Share,” requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

Recent Accounting Pronouncements

In April 2016, the FASB released ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” The ASU includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. While aimed at reducing the cost and complexity of the accounting for share-based payments, the amendments are expected to significantly impact net income, EPS, and the statement of cash flows. Implementation and administration may present challenges for companies with significant share-based payment activities. The ASU is effective for public companies in annual periods beginning after December 15, 2016, and interim periods within those years. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In April 2016, FASB issued Accounting Standards Update No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” The amendments clarify the following two aspects of Topic 606: (a) identifying performance obligations; and (b) the licensing implementation guidance. The amendments do not change the core principle of the guidance in Topic 606. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements in Topic 606. Public entities should apply the amendments for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein (i.e., January 1, 2018, for a calendar year entity). Early application for public entities is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In May 2016, the FASB issued ASU 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting”, The amendments rescinds SEC paragraphs pursuant to two SEC Staff Announcements at the March 3, 2016 Emerging Issues Task Force (EITF) meeting. Specifically, registrants should not rely on the following SEC Staff Observer comments upon adoption of Topic 606: 1) Revenue and Expense Recognition for Freight Services in Process, which is codified in paragraph 605-20-S99-2; 2) Accounting for Shipping and Handling Fees and Costs, which is codified in paragraph 605-45-S99-1; 3) Accounting for Consideration Given by a Vendor to a Customer (including Reseller of the Vendor's Products), which is codified in paragraph 605-50-S99-1; 4) Accounting for Gas-Balancing Arrangements (i.e., use of the "entitlements method"), which is codified in paragraph 932-10-S99-5, which is effective upon adoption of ASU 2014-09. The Company is currently in the process of evaluating the impact of the adoption on its consolidated financial statements.

F-20


In May 2016, the FASB issued ASU 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients". The amendments, among other things: (1) clarify the objective of the collectability criterion for applying paragraph 606-10-25-7; (2) permit an entity to exclude amounts collected from customers for all sales (and other similar) taxes from the transaction price; (3) specify that the measurement date for noncash consideration is contract inception; (4) provide a practical expedient that permits an entity to reflect the aggregate effect of all modifications that occur before the beginning of the earliest period presented when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations; (5) clarify that a completed contract for purposes of transition is a contract for which all (or substantially all) of the revenue was recognized under legacy GAAP before the date of initial application, and (6) clarify that an entity that retrospectively applies the guidance in Topic 606 to each prior reporting period is not required to disclose the effect of the accounting change for the period of adoption. The effective date of these amendments is at the same date that Topic 606 is effective. The Company is currently in the process of evaluating the impact of the adoption on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”) which requires credit losses on available-for-sale debt securities to be presented as an allowance rather than as a write-down. This approach is an improvement to current GAAP because an entity will be able to record reversals of credit losses (in situations in which the estimate of credit losses declines) in current period net income, which in turn should align the income statement recognition of credit losses with the reporting period in which changes occur. Current GAAP prohibits reflecting those improvements in current period earnings. ASU 2016-13 is effective for interim and annual periods beginning after December 15, 2019, and requires a modified retrospective approach to adoption. Early adoption is permitted for interim and annual periods beginning after December 15, 2018. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and related disclosures.

NOTE 3 - ASSETS SALE

On December 24, 2014, Humankind entered into a stock transfer agreement (the “Agreement”) with Xiuzheng Pharmaceutical Group Co., Ltd. a company incorporated under the laws of the People’s Republic of China and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), Mr. Xin Sun, the CEO of the Company, and Huimeijia, pursuant to which, Humankind and Mr. Xin Sun (the “Equity Holders”), shall sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of the 100% equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) to the Equity Holders.

F-21


On February 9, 2015, the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy. The Equity Holders will retain the equity interests in Huimeijia, but will have the equity interests pledged to Xiuzheng Pharmacy until the Assets are transferred, at which time all the cash consideration shall be paid by the Buyer. The total cash consideration remains to be the same as under the Agreement, i.e., RMB 8,000,000 (approximately $1,306,186) to the Assets Transferors. In the event that the Assets are failed to be transferred to the Buyer due to the fault of the Assets Transferors, the paid consideration shall be returned to the Buyer with interests accrued. If the failure of the transfer of the Assets is a result of the government policy changes or force majeure, the paid cash consideration shall be returned to the Buyer but without any interests.

As of June 30, 2016, the transfer of the Assets had not been completed because the assets transfer crossed different provinces which resulted in a complicated interaction among the local administrations of Heilongjiang Province, where Huimeijia is located and Jilin Province, where the transferee is located. The Company is striving to accelerate the process of the transfer.

NOTE 4 - ACCOUNTS RECEIVABLE

The Company’s accounts receivable amounted to $1,145,131 and $1,431,298, respectively, net of allowance for doubtful accounts amounting to $52,129 and $45,489 as of June 30, 2016 and 2015, respectively.

NOTE 5 - INVENTORIES

Inventory consists of following:

    June 30, 2016     June 30, 2015  
Raw Materials $  122,569   $  189,004  
Supplies and Packing Materials   130,472     19,565  
Work-in-Progress   118,233     261,019  
Finished Goods   48,713     371,651  
Total $  419,987   $  841,239  

F-22


For the years ended June 30, 2016 and 2015, the Company has not made provision for inventory in regards to excessive, slow moving or obsolete items.

NOTE 6 - CONSTRUCTION IN PROGRESS

Construction in progress consisted of the following:

    June 30, 2016     June 30, 2015  
Plant - HLJ Huimeijia $  670,051   $  605,542  
Plant and Production Lines - Huimeijia   1,806     1,935  
Total $  671,857   $  607,477  

On April 6, 2012, HLJ Huimeijia entered into an agreement with a contractor for the plant, the estimated total cost of construction was approximately $2.09 million (RMB 12,800,000), anticipated to be completed by December 2016. As of June 30, 2016, 35% of construction had been completed and $670,051 (RMB 4,453,093) had been recorded as a cost of construction in progress.

NOTE 7 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

    June 30, 2016     June 30, 2015  
Building, Warehouses and Improvements $  4,360,191   $  4,673,771  
Machinery and Equipment   1,232,861     1,226,433  
Office Equipment   69,330     134,932  
Vehicles   204,457     232,511  
Less Accumulated Depreciation   (1,998,278 )   (1,952,553 )
Total $  3,868,561   $  4,315,094  

Depreciation expense was $255,330 and $364,932 for the years ended June 30, 2016 and 2015, respectively. Depreciation expense charged to operations was $136,822 and $141,753 for the years ended June 30, 2016 and 2015, respectively. Depreciation expense charged to cost of goods sold was $118,508 and $223,179 for the years ended June 30, 2016 and 2015, respectively.

As of June 30, 2016, the building of HLJ Huimeijia with the book value of $1,676,627 has been mortgaged for the working capital loan in the principal amount of $1,504,687 (RMB 10,000,000). As of June 30, 2015, the building of HLJ Huimeijia in the book value of $1,797,209 has been mortgaged for the working capital loan in the principal amount of $1,612,903 (RMB 10,000,000).

F-23


NOTE 8 - INTANGIBLE ASSETS

The following is a summary of intangible assets:

    June 30, 2016     June 30, 2015  
Land Use Rights – Humankind $  953,670   $  1,022,255  
Health Supplement Product Patents – Humankind   4,514,061     4,838,709  
Pharmaceutical Patents - HLJ Huimeijia   134,817     144,514  
Land Use Rights - HLJ Huimeijia   652,295     699,208  
Less: Accumulated Amortization   (2,063,784 )   (1,692,389 )
Total $  4,191,059   $  5,012,297  

All land in the PRC belongs to the State. Enterprises and individuals can pay the State a fee to obtain the right to use a piece of land for commercial purposes or residential purposes for an initial period of 50 years or 70 years, respectively. The land use right can be sold, purchased, and exchanged in the market. The successor owner of the land use right will have the right to use the land for the time remaining on the initial period.

Amortization expense charged to operations was $500,409 and $443,925 for the years ended June 30, 2016 and 2015, respectively.

As of June 30, 2016, land use rights of HLJ Huimeijia with the book value of $652,295 have been mortgaged for a working capital loan in the principal amount of $1,504,687 (RMB 10,000,000). As of June 30, 2015, land use rights of HLJ Huimeijia with a book value of $699,208 have been mortgaged for a working capital loan in the principal amount of $1,612,903(RMB 10,000,000).

NOTE 9 - SHORT-TERM LOAN

On November 12, 2015, HLJ Huimeijia entered into a short-term loan agreement with a bank for a working capital loan in the principal amount of RMB 10,000,000, at an interest rate of 5.66% from November 12, 2015 to November 10, 2016. The loan was secured by the land use right and the building of HLJ Huimeijia, with a maturity date of November 10, 2016. As of June 30, 2016 and 2015, the Company’s short-term loan was $1,504,687 and $1,612,903, respectively.

Interest expenses were $102,253 and $125,608 for the years ended June 30, 2016 and 2015, respectively.

F-24


NOTE 10 - RELATED PARTY DEBTS

Related party debts, which represent temporary short-term loans from Mr. Xin Sun and Mr. Kai Sun consisted of the following:

    June 30, 2016     June 30, 2015  
Mr. Xin Sun $  2,678,220   $  1,872,830  
Mr. Kai Sun   35,186     37,716  
Total $  2,713,406   $  1,910,546  

These loans are unsecured and non-interest bearing and have no fixed terms of repayment; therefore, they are deemed payable on demand. Mr. Kai Sun is a PRC citizen and a family member of Mr. Xin Sun, the CEO of the Company.

NOTE 11 - INCOME TAXES

(a) Corporate income taxes

United States

China Health US was organized in the United States. China Health US had no taxable income for US income tax purposes for the years ended June 30, 2016 and 2015, respectively. As of June 30, 2016, China Health US has a net operating loss carry forward for United States income taxes. Net operating loss carry forwards are available to reduce future years’ taxable income. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s operating history and the continued losses of the US entity. Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset to reduce the asset to zero. There were no changes in the valuation allowance for the years ended June 30, 2016 and 2015. Management reviews this valuation allowance periodically and makes adjustments accordingly.

Hong Kong

China Health HK was incorporated in Hong Kong and is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. No provision for income taxes have been made as China Health HK has no taxable income in Hong Kong.

F-25


People’s Republic of China

Under the EIT Law, the standard EIT rate is 25%. The PRC subsidiaries of the Company are subject to PRC income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which they operate.

The provision for income taxes on income consists of the following for the years ended June 30, 2016 and 2015:

Provision for income taxes consisted of:

    For the Years Ended  
    June 30,  
    2016     2015  
Current provision:            
USA $  -   $  -  
China   343,986     234,905  
Total current provision   343,986     234,905  
Deferred provision:            
USA   -     -  
China   -     -  
Total deferred provision   -     -  
Total provision for income taxes $  343,986   $  234,905  

Significant components of deferred tax assets were as follows:

    June 30, 2016     June 30, 2015  
Deferred tax assets            
Net operating loss carry forward $  118,259   $  141,735  
Allowance for doubtful accounts   -     -  
Valuation allowance   (118,259 )   (141,735 )
Deferred tax assets, net $  -   $  -  

As of June 30, 2016 and 2015, the Company accrued a 100% valuation allowance on its deferred tax assets based on the assessment on the probability of future reversion.

(b) Uncertain tax positions

There were no unrecognized tax benefits as of June 30, 2016 and 2015, respectively. Management does not anticipate any potential future adjustments in the next twelve months which would result in a material change to its tax positions. For the years ended June 30, 2016 and 2015, the Company did not incur any interest and penalties arising from its tax payments.

F-26


NOTE 12 - EARNINGS PER SHARE

Basic earnings per common share is computed by dividing net earnings applicable to common shareholders by the weighted-average number of common shares outstanding during the period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants.

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

For the years ended June 30, 2016 and 2015, the Company does not have potential dilutive shares.

The following table sets forth the computation of basic and diluted net income per share:

    For the Years Ended  
          June 30,  
    2016     2015  
Net income attributable to the common stockholders $  159,602   $  2,561  
             
Basic weighted average outstanding shares of common stock   65,616,175     63,044,395  
Dilutive effect of options and warrants   -     -  
Diluted weighted average common stock and common stock equivalents $  65,616,175   $  63,044,395  
             
Earnings per share:            
Basic $  0.002   $  0.000  
Diluted $  0.002   $  0.000  

NOTE 13 - COMMITMENTS AND CONTINGENCIES

The Company’s assets are located in the PRC and revenues are derived from operations in the PRC.

F-27


In terms of industry regulations and policies, the economy of the PRC has been transitioning from a planned economy to market oriented economy. Although in recent years the Chinese government has implemented measures emphasizing the utilization of market forces for economic reforms, the reduction of state ownership of productive assets and the establishment of sound corporate governance in business enterprises, a substantial portion of productive assets in the PRC is still owned by the Chinese government. For example, all land is state owned and leased to business entities or individuals through the government’s granting of Land Use Rights. The granting process is typically based on government policies at the time of granting and can be lengthy and complex. This process may adversely affect the Company’s future manufacturing expansions. The Chinese government also exercises significant control over the PRC’s economic growth through the allocation of resources and providing preferential treatment to particular industries or companies. Uncertainties may arise with changing of governmental policies and measures.

The Company faces a number of risks and challenges not typically associated with companies in North America and Western Europe, since its assets exist solely in the PRC, and its revenues are derived from its operations therein. The PRC is a developing country with an early stage market economic system, overshadowed by the state. Its political and economic systems are very different from the more developed countries and are in a state of change. The PRC also faces many social, economic and political challenges that may produce major shocks, instabilities and even crises, in both its domestic arena and in its relationships with other countries, including the United States. Such shocks, instabilities and crises may in turn significantly and negatively affect the Company’s performance.

Since the Company terminated its rental agreement on January 9, 2013, it had no rental commitment as of June 30, 2016.

NOTE 14 - MAJOR SUPPLIERS AND CUSTOMERS

The Company had one supplier that accounted for 78% of the Company’s purchases for the year ended June 30, 2016.

The Company had one supplier that accounted for 67% of the Company’s purchases for the year ended June 30, 2015.

The Company had four customers that in the aggregate accounted for 44% of the Company’s total sales for the year ended June 30, 2016, with each customer accounting for 12%, 11%, 11% and 10%, respectively.

F-28


The Company had three customers that in the aggregate accounted for 28% of the Company’s total sales for the year ended June 30, 2015, with each customer accounting for 12%, 10% and 6%, respectively.

NOTE 15 - SEGMENT REPORTING

The Company was organized into three main business segments based on the types of products being provided to customers: HLJ Huimeijia, Humankind and others. Each of the three operating segments referenced above has separate and distinct general ledgers. The chief operating decision maker (“CODM”) receives financial information, including revenue, gross margin, operating income, and net income produced from the various general ledger systems to make decisions about allocating resources and assessing performance; however, the principal measure of segment profitability or loss used by the CODM is net loss by segment.

The following tables present summary information by segment for the years ended June 30, 2016 and 2015, respectively:

    For the Year Ended June 30, 2016     For the Year Ended June 30, 2015  
    HLJ                       HLJ                    
    Huimeijia     Humankind     Others     Consolidated     Huimeijia     Humankind     Others     Consolidated  
Revenues $  703,478   $  7,113,023   $  -   $  7,816,501   $  1,569,807   $  8,656,245   $  -   $  10,226,052  
Cost of revenues   580,479     4,920,644     -     5,501,123     1,203,911     6,086,263     -     7,290,174  
Gross profit   122,999     2,192,379     -     2,315,378     365,896     2,569,982     -     2,935,878  
Interest expense   102,253     -     -     102,253     125,608     -     -     125,608  
Depreciation and amortization   55,629     580,835     767     637,231     72,756     510,987     1,937     585,680  
Income tax   -     343,986     -     343,986     -     234,905     -     234,905  
Net income (loss)   (577,963 )   1,031,957     (294,407 )   159,587 )   (426,579 )   704,714     (275,626 )   2,509  
Total capital expenditures   92,860     444     -     93,304     4,384     17,240     -     21,624  
Total assets $  2,969,121   $  37,258,149   $  51,527   $  40,278,797   $  3,358,615   $  38,082,449   $  64,365   $  41,505,429  

NOTE 16 - STOCK BASED COMPENSATION

On March 27, 2015, the Board of Directors (the “Board”) adopted the Company’s 2015 Equity Incentive Plan (the “Plan”), which became effective as of such date. The Plan is intended to be construed as an employee benefit plan that satisfies the requirements for exemption from the restrictions of Section 16(b) of the Exchange Act. A summary of the principal provisions of the Plan is set forth below.

The aggregate number of shares of common stock that may be issued under the Plan is 6,000,000 shares. In the event that the Board determines that any dividend or other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Stock or other securities of the Company, or other corporate transaction or event affects the common stock such that an adjustment is determined by the Board, in its sole discretion, to be necessary or appropriate in order to prevent dilution or enlargement of benefits or potential benefits intended to be made available under the Plan, the Board may, in such manner as it in good faith deems equitable, adjust any or all of (i) the number of shares of common stock or other securities of the Company (or number and kind of other securities or property) with respect to which awards may be granted, (ii) the number of shares of common stock or other securities of the Company (or number and kind of other securities or property) subject to outstanding awards, and (iii) the exercise price with respect to any stock option, or make provision for an immediate cash payment to the holder of an outstanding award in consideration for the cancellation of such award.

F-29


Individuals eligible for awards under the Plan shall consist of employees (including officers), directors and consultants, or those who will become employees (including officers), directors and consultants, of the Company and/or its subsidiaries whose performance or contribution, in the sole discretion of the Committee, benefits or will benefit the Company or any subsidiary.

The Plan was effective upon its approval by the Board and adoption by the Company. The Plan shall terminate on March 27, 2025, except with respect to awards then outstanding. After such date no further awards shall be granted under the Plan.

On March 30, 2015, the Company granted 3,000,000 and 300,000 restricted shares to Mr. Xin Sun, Chief Executive Officer and Chief Financial Officer of the Company and an employee, respectively. The vesting periods of the restricted shares under the Plan were determined based on individual stock award agreements and was recognized as equity compensation for the fiscal years ended June 30, 2015 and 2016. The grant was pursuant to the Plan and a Restricted Stock Award Agreement, and was based on the exemption afforded by Regulation S under the Securities Act of 1933, as amended.

F-30



Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain a set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in our reports filed under the Securities Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that this information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Based upon their evaluation as of the end of the periods covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective to satisfy the objectives, due to the material weakness in our internal control over financial reporting discussed below.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system was designed to provide reasonable assurance to our management and our sole board member regarding the preparation and fair presentation of published financial statements.

Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2016. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 in Internal Control—Integrated Framework. Our management has implemented and tested our internal control over financial reporting based on these criteria and did not identify any significant deficiencies and material weaknesses as of June 30, 2016. However, based on the fact that we do not have any full-time accounting personnel who have U.S. GAAP experience, our management has considered this as a material weakness and determined that as of June 30, 2016, the internal control over financial reporting was not effective.

In an effort to remedy this material weakness in the future, we intend to do the following:

 

Develop a comprehensive training and development plan, for our finance, accounting and internal audit personnel, including our Chief Financial Officer, Financial Manager, and others, in the principles and rules of U.S. GAAP, SEC reporting requirements and the application thereof.

 

 

 

Design and implement a program to provide ongoing company-wide training regarding the Company’s internal controls, with particular emphasis on our finance and accounting staff.

 

 

 

Implement an internal review process over financial reporting to review all recent accounting pronouncements and to verify that the accounting treatment identified in such report have been fully implemented and confirmed by our internal control department. In the future, we will continue to improve our ongoing review and supervision of our internal control over financial reporting.

 

 

 

Hire an individual that possesses the requisite U.S. GAAP experience and education.

Despite the material weakness reported above, our management believes that our consolidated financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

This report does not include an attestation report of our registered accounting firm regarding internal control over financial reporting. The management’s report was not subject to attestation by our registered public accounting firm because we are a smaller reporting company.

29


Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting have come to management’s attention during our last fiscal year that have materially affected, or are likely to materially affect, our internal control over financial reporting.

Limitations on Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Item 9B. Other Information.

None.

Item 10. Directors, Executive Officers and Corporate Governance.

The following table sets forth information regarding our sole board member and executive officer. Our sole director holds office until the election and qualification of his successor.

Name Age Position
Xin Sun 50 Chairman (sole director), Chief Executive Officer, Chief Financial Officer and Treasurer

Biography

Mr. Xin Sun attended Jia Mu Si Medical College with a major in Pharmacy from 1984 to 1988. From 1988 to 1991, he was the Production Manager at Ha Yao Group Sanchine Medicine Joint-Stock Company Ltd. From 1991 to 1994, he was the District Director for the Northeast District of China for Pfizer Pharmaceuticals Limited. Thereafter, he spent one year as the Director of Marketing for Ha Yao Group Sanchine Medicine Joint-Stock Company Ltd. From 1996 to 2002, he was the Chief Executive Officer of a company he founded, Heilongjiang Bijie Chemical Industry Co., Ltd., which is no longer in existence now. He obtained his Masters of Business Administration from Renmin University of China in 2004. From 2003 to the present, he has been the President and Chief Executive Officer of Humankind. Mr. Sun is also President and General Manager of Huimeijia.

As a result of his professional experience, Mr. Xin Sun is well known in the pharmaceutical field in Harbin, PRC. While he was studying at Renmin University, Mr. Xin Sun developed many contacts in the pharmaceutical field, many of which later became district agents and other employees in Humankind’s distribution system.

Our sole director, Mr. Xin Sun, does not hold any directorships in other reporting companies and does not qualify as an “independent director” under the Rules of NASDAQ, Marketplace Rule 4200(a)(15).

To our knowledge, during the last ten years, none of our directors and executive officers (including those of our subsidiaries) have:

(a) had a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time.

(b) been convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor offenses.

30


(c) been subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities.

(d) been found by a court of competent jurisdiction (in a civil action), the SEC, or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Director Qualifications

Directors are responsible for overseeing the Company’s business consistent with their fiduciary duty to the stockholders. This significant responsibility requires highly-skilled individuals with various qualities, attributes and professional experience. Our sole director believes that there are general requirements for service on the board of directors (the “Board”) that are applicable to all directors and that there are other skills and experience that should be represented on the Board as a whole but not necessarily by each director. The existing board member considers the qualifications of director and director candidates individually and in the broader context of the Board’s overall composition and the Company’s current and future needs.

Qualifications for All Directors

In its assessment of each potential candidate, including those recommended by the stockholders, the Board will consider the nominee’s judgment, integrity, experience, independence, understanding of the Company’s business or other related industries and such other factors it determines are pertinent in light of the current needs of the Board.

The Board also takes into account the ability of a director to devote the time and effort necessary to fulfill his or her responsibilities to the Company.

The Board requires that each director be a recognized person of high integrity with a proven record of success in his or her field. Each director must demonstrate innovative thinking, familiarity with and respect for corporate governance requirements and practices, an appreciation of multiple cultures and a commitment to sustainability and to dealing responsibly with social issues. In addition to the qualifications required of all directors, the Board conducts interviews of potential director candidates to assess intangible qualities including the individual’s ability to ask difficult questions and, simultaneously, to work collegially. The Board does not have a specific diversity policy, but considers diversity of race, ethnicity, gender, age, cultural background and professional experiences in evaluating candidates for Board membership. Diversity is important because a variety of points of view contribute to a more effective decision-making process.

Qualifications, Attributes, Skills and Experience to be Represented on the Board as a Whole

The Board has identified particular qualifications, attributes, skills and experiences that should be represented on the Board as a whole, in light of the Company’s current needs and its business priorities. The Board believes that it should include some directors with a high level of financial literacy and some directors who possess relevant business experiences as a chief executive officer, president or similar position at a company. Marketing is the core focus of our business and the Company seeks to develop and deploy innovative and effective marketing and technology. Therefore, the Board believes that marketing and technology experience should be represented on the Board.

Presently, Mr. Xin Sun is the sole director of the Company. Mr. Xin Sun possesses many of the skills and experiences needed for our business. He has experience in the pharmaceutical industry, having previously been the District Director for the Northeast District of China for Pfizer Pharmaceuticals Limited from 1991 to 1994. He has also been the Director of Marketing for Ha Yao Group Sanchine Medicine Joint-Stock Company Ltd., where he acquired strong marketing experience. From 1996 to 2002, Mr. Xin Sun was the chief executive officer of a company he founded, Heilongjiang Bijie Chemical Industry Co., Ltd., and from 2003 to the present, he has been the president and chief executive officer of Humankind.

The Board plans to eventually increase its membership to include directors with skills and experiences complementary to Mr. Xin Sun’s background.

31


Board Leadership Structure and Role in Risk Oversight

Mr. Xin Sun is the Company’s Chairman and Chief Executive Officer. The Board’s role in the risk oversight of the Company includes, among other things:

-

appointing, retaining and overseeing the work of the independent auditors, including resolving disagreements between the management and the independent auditors relating to financial reporting;

 

 

-

approving all auditing and non-auditing services permitted to be performed by the independent auditors;

 

 

 

-

reviewing annually the independence and quality control procedures of the independent auditors;

 

 

 

-

reviewing and approving all proposed related party transactions;

 

 

 

-

discussing the annual audited financial statements with the management; and

 

 

-

meeting separately with the independent auditors to discuss critical accounting policies, management letters, recommendations on internal controls, the auditor’s engagement letter and independence letter and other material written communications between the independent auditors and the management.

Compliance with Section 16(a) of Exchange Act

Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than ten percent of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common stock and other equity securities, on Form 3, 4 and 5 respectively. Executive officers, directors and greater than ten percent shareholders are required by the SEC regulations to furnish the Company with copies of all Section 16(a) reports they file.

Based solely on our review of the copies of such reports, we believe that, with respect to the fiscal years ended June 30, 2016 there is no triggering event for the filing of any report under Section 16(a) by our sole officer and director, or by any of the persons known to us to own more than ten percent of our common stock

Meetings of Our Board of Directors

The Board held no meetings; however, the Board had resolved matters in written consent one time during the fiscal year ended June 30, 2016.

Board Committees

Audit Committee. We intend to establish an audit committee of the Board which will consist of soon-to-be-nominated independent directors. The audit committee’s duties will be to recommend to the Board the engagement of independent auditors to audit our financial statements and to review our accounting and auditing principles. The audit committee will review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent public accountants, including their recommendations to improve the system of accounting and internal controls. The audit committee will at all times be composed exclusively of directors who are, in the opinion of the Board, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.

Audit Committee Financial Expert. The Board currently acts as our audit committee. Since we are still a developing company, the Board is still in the process of finding an “audit committee financial expert” as defined in Regulation S-K and directors that are “independent” as that term is used in Section 10A of the Exchange Act.

32


Compensation Committee. We intend to establish a compensation committee of the Board. The compensation committee will review and approve our salary and benefits policies, including compensation of executive officers.

Code of Ethics

We currently do not have a Code of Ethics because we presently only have one director and one officer. We plan to adopt a Code of Ethics when the size of the Board and management increases.

Director Compensation

We did not compensate our director for the fiscal year ended June 30, 2016. Going forward, however, we intend to implement a market-based director compensation program.

Limitations on Liability

Under Delaware law, a corporation may indemnify its officers, directors, employees and agents under certain circumstances, including indemnification of such persons against liability under the Securities Act. Those circumstances include that an officer, director, employee or agent may be indemnified if the person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

Article Seventh of our Articles of Incorporation provides that no director shall be personally liable to the Company or the stockholders for monetary damages for any breach of fiduciary duty by such person in his or her capacity as a director. Notwithstanding the foregoing sentence, a director shall be liable to the extent provided by applicable law, (i) for breach of his or her duty of loyalty to the Company or the stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the Delaware General Corporation law, or (iv) for any transaction from which he or she derived an improper personal benefit. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Company for or with respect to any acts or omissions of such director occurring prior to such amendment.

We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his or her actions, whether or not the Delaware General Corporation Law would permit indemnification.

Indemnification against Public Policy

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling an issuer pursuant to the foregoing provisions, the opinion of the SEC is that such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than by a director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The effect of indemnification may be to limit the rights of the Company and the stockholders (through stockholders’ derivative suits on behalf of the Company) to recover monetary damages and expenses against a director for breach of fiduciary duty.

Directors and Officers of Humankind

The following table sets forth certain information as of June 30, 2016 concerning the directors and executive officers of Humankind:

33



Directors and Executive Officers Position/Title Age
Xin Sun Chairman, Chief Financial Officer, Treasurer 50
Baosen Ma President, Secretary, Director 48
Kai Sun Director 45

The following is a summary of the biographical information of those directors and officers of Humankind whose biographical information does not appear above:

Baosen Ma, President, Secretary and Director

Mr. Baosen Ma graduated from China University of Political Science and Law with a major in Financial Accounting. From 1987 to 1992, he was an accountant with Harbin Keluola Solar Power Co., Ltd. Thereafter, from 1992 to 1996, he was Vice General Manager and Sales Manager for Shanghai Dahua Solar Battery Co., Ltd. From 1996 to 2004, he was the East China Manager for the Ha Yao Group Sanchine Medicine Joint-Stock Ltd. In January 2004, Mr. Ma was appointed President, Secretary and Director of Humankind.

Kai Sun, Director

Mr. Kai Sun graduated from Mu Dan Jiang University with a major in Economics. From 1993 to 1995, he was Vice Director of Mu Dan Jiang Engine Factory. Thereafter, from 1995 to 1998, he was a Director at Mu Dan Jiang Engine Factory. From 1998 to 2004, he was an Administration Director for Mu Dan Jiang Lysine Co., Ltd. Since 2004, he has been the Administration Director at Humankind. Mr. Kai Sun is the younger brother of Mr. Xin Sun, the Company’s Chairman, Chief Financial Officer, Treasurer and sole director. In January 2004, Mr. Kai Sun was appointed a director of Humankind.

Item 11. Executive Compensation.

The following Summary Compensation Table sets forth, for the years indicated, all cash compensation paid, distributed or accrued for services, including salary and bonus amounts, rendered in all capacities by our Chief Executive Officer and all other executive officers who received or are entitled to receive remuneration in excess of $100,000 during the stated periods. Mr. Xin Sun, our Chief Executive Officer and sole director, receives no additional compensation for the services he provides in his capacity as director.

SUMMARY COMPENSATION TABLE

(all figures in US Dollars)

                                  Non-Equity     Non-qualified              
Name                                 Incentive     Deferred     All        
and                                 Plan     Compensation     Other        
Principal         Salary     Bonus     Stock     Option     Compensation     Earnings     Compensation     Total  
Position   Year     ($)     ($)     Awards ($)     Awards ($)     ($)     ($)     ($)     ($)  
                                                       
Xin Sun, Chief Executive Officer, Chief Financial Officer   2016     48,717     0     225,000     N/A     N/A     N/A     N/A     273,717  
    2015     45,095     0     225,000     N/A     N/A     N/A     N/A     270,095  

Employment Agreements

We have no employment agreement with our sole principal executive officer, Mr. Xin Sun.

Equity Compensation Plan Information

34


The following table sets forth information regarding grants of awards to Named Executive Officer during the year ended June 30, 2016:

Grants of Plan-Based Awards

    Estimated future payouts under     Estimated future payouts under           All other              
    non-equity incentive plan awards     equity incentive plan awards           option              
                                              All other     awards:           Grant  
                                              stock     Number           date  
                                              awards:     of           fair  
                                              Number     securities     Exercise or     value of  
                                              of shares     underlyin     base price     stock  
    Gran                                         of stock     g     of option     and  
    t     Threshold(     Target($)     Maximum($     Threshold(#     Target(#)     Maximum(#     or     options(#)     awards($/Sh     option  
Name   date   $ )           )     )           )     units(#)           )     awards  
(a)   (b)      (c)     (d)     (e)     (f)     (g)     (h)     (i)     (j)     (k)     (l)  
Xin Sun, Chief Executiv e Officer, Chief Financia l Officer   -     -     -     -     -     -     -     3,000,000 (1)   -   $ 0.15   $ 225,000  

(1) Among 3,000,000 shares of restricted shares of common stock granted to Mr. Xin Sun, 1,500,000 shares vested on May 30, 2015, 1,500,000 shares vested on March 30, 2016.

Outstanding Equity Awards at Fiscal Year-End

   

Option awards

 

 

Stock awards

 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

incentive

 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

plan

 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

incentive

 

 

awards:

 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

plan

 

 

market or

 

   

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

 

awards:

 

 

payout

 

   

 

 

 

 

incentive plan

 

 

 

 

 

 

 

 

 

 

number of

 

 

value of

 

   

 

 

 

 

awards:

 

 

 

 

 

 

 

 

Market

 

 

unearned

 

 

unearned

 

   

Number of

 

 

Number of

 

 

number of

 

 

 

 

 

 

Number of

 

 

value of

 

 

shares,

 

 

shares,

 

   

securities

 

 

securities

 

 

securities

 

 

 

 

 

 

shares or

 

 

shares or

 

 

units or

 

 

units or

 

   

underlying

 

 

underlying

 

 

underlying

 

 

 

 

 

 

units of

 

 

units of

 

 

other rights

 

 

other rights

 

   

unexercised

 

 

unexercised

 

 

unexercised

 

 

Option

 

 

Option

 

 

stock that

 

 

stock that

 

 

that have

 

 

that have

 

   

options(#)

 

 

options(#)

 

 

unearned

 

 

exercise

 

 

expiration

 

 

have not

 

 

have not

 

 

not

 

 

not

 

Name  

exercisable

 

 

unexercisable

 

 

options(#)

 

 

price($)

 

 

date

 

 

vested(#)

 

 

vested(#)

 

 

vested(#)

 

 

vested($)

 

(a)  

(b)

 

 

(c)

 

 

(d)

 

 

(e)

 

 

(f)

 

 

(g)

 

 

(h)

 

 

(i)

 

 

(j)

 

                                                       
Xin Sun, Chief Executive Officer, Chief Financial Officer   -     -     -     -     -     3,000,000     0.19*     -     570,000  

*closing price as of June 30, 2016.

Option Exercises and Stock Vested

   

Option awards

 

 

 

 

Stock awards

 

 

 

   

Number of

 

 

Value

 

 

Number of

 

 

Value

 

   

shares

 

 

realized

 

 

shares

 

 

realized

 

   

acquired

 

 

on

 

 

acquired

 

 

on

 

   

on

 

 

exercise

 

 

on vesting

 

 

vesting

 

Name  

exercise

 

 

($)

 

 

(#)

 

 

($)

 

 

 

(#) 

 

 

 

 

 

 

 

 

 

 

(a)

 

(b)

 

 

(c)

 

 

(d)

 

 

(e)

 

                         
Xin Sun, Chief Executive Officer, Chief Financial Officer   -     -     3 ,000,000   $ 885,000  

35



Directors’ and Officers’ Liability Insurance

We currently do not have insurance insuring directors and officers against liability; however, we are in the process of investigating the availability of such insurance.

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth certain information with respect to the beneficial ownership of our voting securities by (i) any person or group owning more than five percent of any class of voting securities, (ii) our director, (iii) our chief executive officer and president and (iv) all executive officers and directors as a group as of September 14, 2016.

The address of the beneficial owner listed below is Harbin Humankind Biology Technology Co. Limited, 168 Binbei Street, Songbei District, Harbin, Heilongjiang Province, PRC.

  Amount and Nature

Title of

  of

  Percent of Class

Class

  Name Beneficial Owner (1)

 

 

 

 

 

 

Common Stock

 

Xin Sun, Chairman, Chief Executive Officer, Chief Financial Officer and Treasurer

   

20,507,188

   

31.1%

 

 

   

   

 

Common Stock

 

All officers and directors as a group (1 person)

   

20,507,188

   

31.1%

 

(1) Based on 65,839,737 total issued and outstanding shares of the Company as of September 14, 2016.

Mr. Xin Sun has the sole power to vote and dispose of all shares of common stock listed opposite his name. Mr. Sun did not and does not own any options or convertible securities.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

Our company received temporary short-term loans from its majority owner and our sole director and principal executive officer, Mr. Xin Sun, a PRC citizen. These loans are unsecured and non-interest bearing, and have no fixed terms of repayment; therefore, they are deemed payable on demand. Cash flows classified as due to majority owner are classified as cash flows from financing activities. The total borrowings from Mr. Sun were $2,678,220 and $1,872,830 as of June 30, 2016 and June 30, 2015, respectively.

There were no interested imputed on the loans for the fiscal years 2016 and 2015, respectively.

Item 14. Principal Accounting Fees and Services.

We were billed by CANUSWA ACCOUNTING & TAX SERVICES INC, (“Canuswa”), our independent public accountants, for the following professional services they performed for us during the fiscal year ended June 30, 2016 and 2015, as set forth in the table below:

36



  Auditors     Audit     Audit-     Tax     Other  
          Fees     Related     Fees     Fees  
                Fees              
                               
2016   Canuswa   $  154,000                    
2015   Canuswa   $  185,000     -     -     -  
    KCCW     17,500                    

Pre-Approval Policies and Procedures

All of the services rendered to us by our independent registered public accountants were pre-approved by the Board.

37


PART IV

Item 15. Exhibits, Financial Statement Schedules

Exhibit

Filed

Index

Description of Document

Herewith

Incorporated by Reference To:

 

3.1

Articles of Incorporation.

Exhibit 3.1 of the Company’s Registration Statement on Form 10-SB filed with the SEC on December 1, 2004.

 

3.2

By-laws.

Exhibits 3.2 of the Company’s Registration Statement on Form 10-SB filed with the SEC on December 1, 2004.

 

3.3

Certificate of Amendment, dated May 11, 2005.

Exhibits 3.3of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

3.4

Certificate of Amendment, dated November 12, 2008.

Exhibit 3.4 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

3.5

Certificate of Amendment, dated February 11, 2009.

Exhibit 3.5 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

4.1

Specimen of Common Stock Certificate

Exhibit 4.1 of the Company’s Annual Report on Form 10-K filed with the SEC on September 29, 2014.

 

10.1

English Translation of Land Use Agreement, dated June 7, 2004, between Harbin Humankind Biology Technology Co. Limited and Harbin City, Daochu District, Songbei Township, Jinxin Village.

Exhibit 10.3 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

10.2

English Translation of Cooperative Agreement, dated September 17, 2008, between Harbin Humankind Biology Technology Co. Limited and the Commercial Bureau of Qing’an County.

Exhibit 10.5 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

10.3

English Translation of Land Purchase Agreement, dated July 7, 2009, between Harbin Humankind Biology Technology Co. Limited and Harbin Songbei District Construction and Development Management Committee.

Exhibit 10.6 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

10.4

English Translation of Technology Transfer Agreement, dated October 12, 2007, between Harbin Humankind Biology Technology Co. Limited and Beijing Jindelikang Bio- Technology Co., Ltd.

Exhibit 10.7 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

 

10.5

English Translation of Health Food Technology Transfer Agreement, dated January 18, 2013 by and between Harbin Humankind Biology Technology Co., Limited and Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd.

Exhibit 10.22 of the Company’s Annual Report on Form 10-K filed with the SEC on October 15, 2013.

38



10.6

English Translation of Stock Transfer Agreement, dated April 10, 2013, by and between Stockholder of Heilongjiang Huimeijia Pharmaceuticals Co., Ltd, Liyuan Sun and Harbin Humankind Biology Technology Co., Limited. and its addendum dated June 18, 2013.

 

Exhibit 10.23 of the Company’s Annual Report on Form 10-K filed with the SEC on October 15, 2013.

 

 

10.7

English Translation of Stock Transfer Agreement, dated April 10, 2013, by and between Stockholder of Heilongjiang Huimeijia Pharmaceuticals Co., Ltd, Wenbin Zhang and Harbin Humankind Biology Technology Co., Limited. and its addendum dated June 18, 2013.

 

Exhibit 10.24 of the Company’s Annual Report on Form 10-K filed with the SEC on October 15, 2013.

 

 

10.8

English Translation of Purchase Agreement, dated January 7, 2014, between Harbin Humankind Biology Technology Co. Limited and Mr. Shukui Wang.

 

Exhibit 10.10 of the Company’s Annual Report on Form 10-K filed with the SEC on September 29, 2014.

 

 

10.9

English Translation of Stock Transfer Agreement dated December 24, 2014, by and among Harbin Humankind Biology Technology Co., Limited., Xin Sun, Harbin Huimeijia Medicine Company, and Xiuzheng Pharmaceutical Group Co., Ltd.

 

Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2014.

 

 

10.10

English Translation of the Supplementary Agreement dated February 9, 2015, by and among Harbin Humankind Biology Technology Co., Limited., Xin Sun, Harbin Huimeijia Medicine Company, and Xiuzheng Pharmaceutical Group Co., Ltd.

 

Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 13, 2015.

 

 

10.11

China Health Industries Holdings, Inc. 2015 Equity Incentive Plan, effective as of March 27, 2015

 

Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2015.

 

 

10.12

Form of the Restricted Stock Award Agreement

 

Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2015.

 

 

10.13

English Translation of the Financial Management Agreement dated June 1, 2015, between Harbin Humankind Biology Technology Co., Limited and Harbin Hongxiang Investment Guarantee Co., Ltd.

 

Exhibit 10.13 of the Company’s Annual Report on Form 10-K filed with the SEC on October 13, 2015.

 

 

10.14

English Translation of the Financial Management Agreement dated July 20, 2016, between Harbin Humankind Biology Technology Co., Limited and Harbin Hongxiang Investment Guarantee Co., Ltd.

 

x

39



21.1

List of Subsidiaries.

Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on October 13, 2015.

 

31.1

Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

x

 

31.2

Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

x

 

32.1

Certification pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

x

 

101.INS

XBRL Instance Document

 

 

101.SCH

XBRL Taxonomy Extension Schema Document

 

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

 

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

 

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

 

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

40


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CHINA HEALTH INDUSTRIES HOLDINGS, INC.
   
  By: /s/ Xin Sun
   
Date: September 28, 2016 Name: Xin Sun
   
  Title: Chief Executive Officer (principal executive officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Xin Sun

Name: Xin Sun

Title: Chief Executive Officer (principal executive officer),
   
  Chief Financial Officer (principal financial officer and principal accounting officer) and sole director
   
Date: September 28, 2016

41